Национальное руководство минздрав

1. WHO. Noncommunicable Diseases: Mortality (2019). https://www.who.int/gho/ncd/mortality_morbidity/en/.

2. European Strategy for the Prevention and Control of Noncommunicable Diseases. A course for recovery. 2006. (In Russ.) Европейская стратегия профилактики и борьбы с неинфекционными заболеваниями. Курс на оздоровление. 2006. https://www.euro.who.int/__data/assets/pdf_file/0010/76528/E89306R.pdf.

3. Приказ Минздрава РФ от 15 января 2020 г. N 8 “Об утверждении Стратегии формирования здорового образа жизни населения, профилактики и контроля неинфекционных заболеваний на период до 2025 года”. https://www.garant.ru/products/ipo/prime/doc/73421912.

4. Budreviciute A, Damiati S, Sabir DK, et al. Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. Front Public Health. 2020;8:574111. doi:10.3389/fpubh.2020.574111.

5. Federal Law No. 323-FZ of November 21, 2011 “On the Basics of Public Health protection in the Russian Federation” (with amendments and additions). (In Russ.) Федеральный закон от 21 ноября 2011 г. N 323-ФЗ “Об основах охраны здоровья граждан в Российской Федерации” (с изменениями и дополнениями) https://base.garant.ru/12191967.

6. Укрепление здоровья и профилактика заболеваний. Основные термины и понятия. Под ред. Оганова Р. Г., Вялкова А. И. М. ГЭОТАР-Медиа. 2001. 17 с.

7. Глобальные факторы риска для здоровья. ВОЗ. Женева. 2015. 70 с.

8. https://apps.who.int/iris/bitstream/handle/10665/44203/9789244563878_rus.pdf.

9. Приказ Минздрава РФ от 29 октября 2020 № 1177н “Об утверждении Порядка организации и осуществления профилактики неинфекционных заболеваний организации и проведения мероприятий по формированию здорового образа жизни в медицинских организациях”. http://publication.pravo.gov.ru/Document/View/0001202012030043.

10. Госдоклад “О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2020 году”. https://www.rospotrebnadzor.ru/upload/iblock/5fa/gd-seb_02.06-_s-podpisyu_.pdf.

11. Росстат. ЕМИС. Доля граждан, ведущих здоровый образ жизни. https://www.fedstat.ru/indicator/59457.

12. Приказ Минэкономразвития РФ от 29 марта 2019 года № 181 “Об утверждении методики расчета показателя “Доля граждан, ведущих здоровый образ жизни (процент)”. http://docs.cntd.ru/document/554093500.

13. Иванова А. Ю., Долгалев И. В. Формирование риска смертности в зависимости от поведенческих факторов (курение, потребление алкоголя) по результатам 27-летнего проспективного исследования. Кардиоваскулярная терапия и профилактика. 2017;16(5):40-5. doi:10.15829/1728-8800-2017-5-40-45.

14. Драпкина О. М., Елиашевич С. О., Шепель Р. Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2016;(6):73-9. doi:10.15829/1560-4071-2016-6-73-79.

15. Кобякова О. С., Деев И. А., Куликов Е. С. и др. Хронические неинфекционные заболевания: эффекты сочетанного влияния факторов риска. Профилактическая медицина. 2019;22(2):45-50. doi:10.17116/profmed20192202145.

16. WHO. Noncommunicable Diseases: Key Facts. 2018. https://www.who.int/news-room/fact-sheets/detail/noncommunicablediseases.

17. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for SmokingAttributable Disease: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention. 2010.

18. Wang H, Naghavi M, Allen C, et al. Global, regional and national life expectancy, all-cause mortality, and causes pecific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global burden of disease study 2015. Lancet. 2016;388:1459-544. doi:10.1016/S0140-6736(16)31012-1.

19. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Eur Respir J. 2007;29:233-9. doi:10.1183/09031936.00138606.

20. Концевая А. В., Мырзаматова А. О., Муканеева Д. К. и др. Экономический ущерб от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году. Профилактическая медицина. 2019;22(6):18-23.

21. Концевая А. В., Муканеева Д. К., Мырзаматова А. О. и др. Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году. Кардиоваскулярная терапия и профилактика. 2020;19(1):2396. doi:10.15829/1728-8800-2020-1-2396.

22. Rocco L, Fumagalli E, Mirelman AJ, Suhrcke M. Mortality, morbidity and economic growth. PLoS ONE. 2021;16(5):e0251424. doi:10.1371/journal.pone.0251424.

23. Allen LN, Pullar J, Wickramasinghe KK, et al. Evaluation of research on interventions aligned to WHO ‘Best Buys’ for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015. BMJ Glob Health. 2018;3(1):e000535.

24. Saving lives, spending less: the case for investing in noncommunicable diseases. Geneva: WHO; 2021. Licence: CC BY-NC-SA 3.0 IGO.

25. Баланова Ю. А., Концевая А. В., Мырзаматова А. О. и др. Прогноз эффективности мер, направленных на снижение потребления соли в Российской Федерации. Экология человека. 2021;(3):25-33.

26. Guidelines Development. Supporting the distribution of knowledge on prevention and treatment of cardiovascular disease is a major responsibility of the European Society of Cardiology. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development.

27. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies European Heart Journal. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484.

28. Si S, Moss JR, Sullivan TR, et al. Effectiveness of general practice-based health checks: a systematic review and metaanalysis. Br J Gen Pract. 2014;64:e47-53.

29. Khaing W, Vallibhakara SA, Attia J, et al. Effects of education and income on cardiovascular outcomes: A systematic review and metaanalysis. Eur J Prev Cardiol. 2017;24:1032-42. doi:10.1177/2047487317705916.

30. Mihor A, Tomsic S, Zagar T, et al. Socioeconomic inequalities in cancer incidence in Europe: a comprehensive review of population-based epidemiological studies. Radiol Oncol. 2020;54(1):1-13. doi:10.2478/raon-2020-0008.

31. Zhang Y, Chen Ch, Pan X, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;372:n604. doi:10.1136/bmj.n604.

32. Allen L, Williams J, Townsend N, et al. Socioeconomic status and non-communicable disease behavioural risk factors in lowincome and lower-middle-income countries: a systematic review. Lancet Glob Health. 2017;5(3):e277-e289. doi:10.1016/S2214-109X(17)30058-X.

33. Харькова Т. Л., Никитина С. Ю., Андреев Е. М. Зависимость продолжительности жизни от уровня образования в России. Вопросы статистики. 2017;(8):61-9.

34. Концевая А. В., Шальнова С. А., Баланова Ю. А. и др. Социально-экономические градиенты поведенческих факторов риска в Российской популяции (по результатам исследования ЭССЕ-РФ). Кардиоваскулярная терапия и профилактика. 2015;14(4):59-67. doi:10.15829/1728-8800-2015-4-59-67.

35. Estruch R, Ruilope LM, Cosentino F. The year in cardiovascular medicine 2020: epidemiology and prevention. Eur Heart J. 2021;42(8):813-21. doi:10.1093/eurheartj/ehaa1062.

36. Попович М. В., Усова Е. В., Зиновьева В. А. и др. Обзор методических подходов к изучению влияния городских инфраструктур на здоровье проживающего населения. Профилактическая медицина. 2021;24(8):23-30.

37. Simos J, Spanswick L, Palmer N, Christie D. The role of health impact assessment in Phase V of the Healthy Cities European Network. Health Promot Int. 2015;30 Suppl 1:i71-i85. doi:10.1093/heapro/dav032.

38. Gaglioti AH, Xu J, Rollins L, et al. Neighborhood Environmental Health and Premature Death From Cardiovascular Disease. Prev Chronic Dis. 2018;15:E17. doi:10.5888/pcd15.170220.

39. Malambo P, Kengne AP, De Villiers A, et al. Built Environment, Selected Risk Factors and Major Cardiovascular Disease Outcomes: A Systematic Review. PLoS One. 2016;11(11):e0166846. doi:10.1371/journal.pone.0166846.

40. Максимов С. А., Артамонова Г. В. Городское планирование, инфраструктура проживания и физическая активность: постановка проблемы и методические подходы (сообщение 1). Профилактическая медицина. 2020;23(1):135-41.

41. Story M, Kaphingst KM, Robinson-O’Brien R, Glanz K. Creating healthy food and eating environments: policy and environmental approaches. Annu Rev Public Health. 2008;29:253-72. doi:10.1146/annurev.publhealth.29.020907.090926.

42. Holsten JE. Obesity and the community food environment: a systematic review. Public Health Nutr. 2009;12(3):397-405. doi: 10.1017/S1368980008002267.

43. Bucher T, Collins C, Rollo ME, et al. Nudging consumers towards healthier choices: a systematic review of positional influences on food choice. Br J Nutr. 2016;115(12):2252-63. doi:10.1017/S0007114516001653.

44. Laska MN, Hearst MO, Forsyth A, et al. Neighbourhood food environments: are they associated with adolescent dietary intake, food purchases and weight status? Public Health Nutr. 2010;13(11):1757-63. doi:10.1017/S1368980010001564.

45. Lee H. The role of local food availability in explaining obesity risk among young school-aged children. Soc Sci Med. 2012;74(8):1193-203. doi:10.1016/j.socscimed.2011.12.036.

46. Drewnowski A, Moudon AV, Jiao J, et al. Food environment and socioeconomic status influence obesity rates in Seattle and in Paris. Int J Obes (Lond). 2014;38(2):306-14. doi:10.1038/ijo.2013.97.

47. Piacentini M, Hibbert S, Al-Dajani H. Diversity in deprivation: exploring the grocery shopping behaviour of disadvantaged consumers. Int Rev Retail Distrib Consum Res. 2001;11:141-58.

48. Freedman D. Local food environments: they’re all stocked differently. Am J Community Psychol. 2009;44(3-4):382-93.

49. Gerritsen S. Renker-Darby A., Harré S. et al. Improving low fruit and vegetable intake in children: Findings from a system dynamics, community group model building study. PLoS One. 2019;14(8):e0221107.

50. Bostean G, Sanchez L, Lippert A. Sociodemographic disparities in e-cigarette retail environment: Vape stores and census tract characteristics in Orange County. Health Place. 2018;50:65-72.

51. Chido-Amajuoyi OG, Ozigbu CE, Zhang K. School proximity and census tract correlates of e-cigarette specialty retail outlets (vape shops) in central Texas. Prev Med Rep. 2020;18:101079. doi: 10.1016/j.pmedr.2020.101079.

52. Marashi-Pour S, Cretikos M, Lyons C, et al. The association between the density of retail tobacco outlets, individual smoking status, neighbourhood socioeconomic status and school locations in New South Wales, Australia. Spat Spatiotemporal Epidemiol. 2015;12:1-7. doi:10.1016/j.sste.2014.09.001.

53. WHO/ILO. Almost 2 Million People Die from Work-Related Causes Each Year. https://www.who.int/news/item/16-09-2021-who-ilo-almost-2-million-people-die-from-work-related-causeseach-year.

54. WHO/ILO Joint Estimates of the Work-Related Burden of Disease and Injury, 2000-2016: Global Monitoring Report. Geneva: WHO. 2021. https://www.who.int/publications-detailredirect/9789240034945.

55. Pega F, Náfrádi B, Momen NC, et al. Global, regional, and national burdens of ischemic heart disease and stroke attributable to exposure to long working hours for 194 countries, 2000-2016: A systematic analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Environ Int. 2021;154:106595. doi:10.1016/j.envint.2021.106595.

56. Tsutsumi A, Kayaba K, Ishikawa S. Impact of occupational stress on stroke across occupational classes and genders. Soc Sci Med. 2011;72(10):1652-8. doi:10.1016/j.socscimed.2011.03.026.

57. ENWHP — European Network for Workplace Health Promotion, A Guide to Promoting Mental Health in the Workplace: Employer’s Resource, ENWHP. WHO. Business Meeting, Edinburg. 2021. https://www.enwhp.org/resources/toolip/doc/2018/04/23/mentalhealth_broschuere_arbeitgeber.pdf.

58. Pandalai SP, Schulte PA, Miller DB. Conceptual heuristic models of the interrelationships between obesity and the occupational environment. Scand J Work Environ Health. 2013;39(3):221-32. doi:10.5271/sjweh.3363.

59. Brisson C, Larocque B, Moisan J, et al. Psychosocial factors at work, smoking, sedentary behavior, and body mass index: a prevalence study among 6995 white collar workers. J Occup Environ Med. 2000;42(1):40-6. doi:10.1097/00043764-200001000-00011.

60. Chau JY, van der Ploeg HP, Merom D, et al. Cross-sectional associations between occupational and leisure-time sitting, physical activity and obesity in working adults. Prev Med. 2012;54(3-4):195-200. doi:10.1016/j.ypmed.2011.12.020.

61. Villareal DT, Apovian CM, Kushner RF, Klein S; American Society for Nutrition; NAASO, The Obesity Society. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82(5):923-34. doi:10.1093/ajcn/82.5.923.

62. Snijder CA, Brouwers MM, Jaddoe VW, et al. Occupational exposure to endocrine disruptors and time to pregnancy among couples in a large birth cohort study: the Generation R Study. Fertil Steril. 2011;95(6):2067-72. doi:10.1016/j.fertnstert.2011.02.017.

63. Brophy JT, Keith MM, Watterson A, et al. Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study. Environ Health. 2012;11:87. doi:10.1186/1476-069X-11-87.

64. Ostry AS, Radi S, Louie AM, LaMontagne AD. Psychosocial and other working conditions in relation to body mass index in a representative sample of Australian workers. BMC Public Health. 2006;6:53. doi:10.1186/1471-2458-6-53.

65. Heraclides AM, Chandola T, Witte DR, Brunner EJ. Work stress, obesity and the risk of type 2 diabetes: gender-specific bidirectional effect in the Whitehall II study. Obesity (Silver Spring). 2012;20(2):428-33. doi:10.1038/oby.2011.95.

66. Tsurugano S, Nakao M, Takeuchi T, et al. Job stress strengthens the link between metabolic risk factors and renal dysfunction in adult men. Tohoku J Exp Med. 2012;226(2):101-8. doi:10.1620/tjem.226.101.

67. Salgado-Delgado R, Angeles-Castellanos M, Buijs MR, Escobar C. Internal desynchronization in a model of night-work by forced activity in rats. Neuroscience. 2008;154(3):922-31. doi:10.1016/j.neuroscience.2008.03.066.

68. Mavanji V, Billington CJ, Kotz CM, Teske JA. Sleep and obesity: a focus on animal models. Neurosci Biobehav Rev. 2012;36(3):1015-29. doi:10.1016/j.neubiorev.2012.01.001.

69. Lowden A, Moreno C, Holmbäck U, et al. Eating and shift work — effects on habits, metabolism and performance. Scand J Work Environ Health. 2010;36(2):150-62. doi:10.5271/sjweh.2898.

70. Kovacic JC, Castellano JM, Fuster V. Cardiovascular defense challenges at the basic, clinical, and population levels. Ann N Y Acad Sci. 2012;1254:1-6. doi:10.1111/j.1749-6632.2012.06495.x.

71. Gan WQ, Davies HW, Demers PA. Exposure to occupational noise and cardiovascular disease in the United States: the National Health and Nutrition Examination Survey 1999-2004. Occup Environ Med. 2011;68(3):183-90. doi:10.1136/oem.2010.055269.

72. Attarchi M, Dehghan F, Safakhah F, et al. Effect of exposure to occupational noise and shift working on blood pressure in rubber manufacturing company workers. Ind Health. 2012;50(3):205-13. doi:10.2486/indhealth.ms1321.

73. WHO. IARC is An Organization that has no Analogues in the Study of Cancer in Order to Prevent it. WHO. 2021. https://www.iarc.who.int/wp-content/uploads/2021/05/IARC-brochure_05-2021_RU.pdf.

74. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens. Part C: Arsenic, Metals, Fibres, and Dusts. IARC Monogr Eval Carcinog Risks Hum. Lyon, France. 2009. https://publications.iarc.fr/120.

75. Asbestos — Hazards and Safe Practice for Clear-up After Tsunami. Geneva: WHO. 2006. https://www.who.int/publications/m/item/asbestos—hazards-and-safe-practice-forclear-up-after-tsunami.

76. Chrysotile Asbestos. Geneva: WHO. 2014. https://www.who.int/ipcs/assessment/public_health/chrysotile_asbestos_summary.pdf.

77. Wolf J, Prüss-Ustün A, Ivanonv I, et al. Preventing Disease Through a Healthier and Safer Workplace. [Electronic resource]. Geneva: WHO. 2018. https://apps.who.int/iris/handle/10665/272980.

78. Asbestos: Elimination of Asbestos-Related Diseases. Geneva: WHO. 2018. https://www.who.int/news-room/fact-sheets/detail/asbestos-elimination-of-asbestos-related-diseases.

79. IARC. Benzene. IARC Monogr Eval Carcinog Risks Hum. Lyon: International Agency for Research on Cancer. 2018. https://publications.iarc.fr/576.

80. Preventing Disease Through Healthy Environments: Exposure to Benzene: a Major Public Health Concern. Geneva: WHO. 2019. https://apps.who.int/iris/handle/10665/329481.

81. Chemicals Road Map. Geneva: WHO. 2017. https://www.who.int/publications/i/item/WHO-FWC-PHE-EPE-17.03.

82. IARC. Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry. IARC Monogr Eval Carcinog Risks Hum. Lyon: International Agency for Research on Cancer. 1993. https://publications.iarc.fr/76.

83. IARC. Diesel and Gasoline Engine Exhausts and Some Nitroarenes. IARC Monogr Eval Carcinog Risks Hum. Lyon: International Agency for Research on Cancer. 2014. https://publications.iarc.fr/129.

84. Environmental Health Criteria 171: Diesel Fuel and Exhaust Emissions. International Programme on Chemical Safety. Geneva: WHO. 1996. https://apps.who.int/iris/bitstream/handle/10665/41865/9241571713-eng.pdf?sequence=1.

85. IARC. Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol. IARC Monogr Eval Carcinog Risks Hum. Lyon: International Agency for Research on Cancer. 2006. http://publications.iarc.fr/106.

86. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax. 2009;64(1):6-12. doi:10.1136/thx.2008.099390.

87. Working Environment (Air Pollution, Noise and Vibration) Convention (No. 148). Geneva: ILO. 1977. https://www.ilo.org/dyn/normlex/en/f?p=NORMLEXPUB:12100:0::NO::P12100_ILO_CODE:C148.

88. Driscoll T, Steenland K, Nelson D, James L. Occupational Airborne Particulates: Assessing the Environmental Burden of Disease at National and Local Levels. Environmental Burden of Disease Series, No. 7. Geneva: WHO. 2004. https://apps.who.int/iris/handle/10665/42994.

89. Maximum Weight Convention (No. 127). Geneva: ILO. 1967. https://www.ilo.org/dyn/normlex/en/f?p=NORMLEXPUB:12100:0::NO::P12100_ILO_CODE:C127.

90. Guide to Developing Balanced Working Time Arrangements. Geneva: ILO. 2019. https://www.ilo.org/travail/info/publications/WCMS_706159/lang—en/index.htm.

91. Workplace Stress. A Collective Challenge. Italy: ILO. 2016. https://www.ilo.org/wcmsp5/groups/public/—ed_protect/—protrav/—safework/documents/publication/wcms_466547.pdf.

92. Модельные корпоративные программы укрепления здоровья работающих. Электронный портал Министерства здравоохранения РФ minzdrav.gov.ru. 2019. https://minzdrav.gov.ru/news/2019/08/01/12153-podgotovlenabiblioteka-korporativnyh-programm-po-ukrepleniyu-zdorovyarabotayuschih-grazhdan.

93. Stress Prevention at Work Checkpoint. Geneva: ILO. 2012. https://www.ilo.org/wcmsp5/groups/public/—dgreports/—dcomm/—publ/documents/publication/wcms_168053.pdf.

94. Pedersen SS, von Känel R, Tully PJ, Denollet J. Psychosocial perspectives in cardiovascular disease. Eur J Prev Cardiol. 2017;24(3_suppl):108-15. doi:10.1177/2047487317703827.

95. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100-10.

96. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137(20):2166-78. doi:10.1161/CIRCULATIONAHA.117.02965.

97. Kotova MB, Rozanov VB, Kiselev AR, et al. Association of Vital Exhaustion with Risk Factors for Cardiovascular Diseases, Quality of Life and Lifestyle in 41–44-Year-Old Muscovite Men. Int. J. Environ. Res. Public Health. 2021;18:9691. doi:10.3390/ijerph18189691.

98. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108:1175-96. doi:10.1007/s00392-019-01488-w.

99. Liu M-Y, Li N, Li WA, et al. Association between psychosocial stress and hypertension: a systematic review and meta-analysis. Neurol. Res. 2017;39(6):573-80. doi:10.1080/01616412.2017.1317904.

100. Argentieri MA, Seddighzadeh B, Noveroske Philbrick S, et al. A Roadmap for conducting psychosocial research in epidemiological studies: perspectives of cohort study principal investigators. BMJ Open. 2020;10(7):e037235. doi:10.1136/bmjopen-2020-037235.

101. Gawlik KS, Melnyk BM, Tan A. Associations Between Stress and Cardiovascular Disease Risk Factors Among Million Hearts Priority Populations. Am J Health Promot. 2019;33(7):1063-66. doi:10.1177/0890117119847619.

102. OSHWiki contributors. Psychosocial risks and workers health. 2020. http://oshwiki.eu/index.php?title=Psychosocial_risks_and_workers_health&oldid=252881.7 February 2021.

103. European Statistical Recovery Dashboard. 2021. 2021:251-5. doi:10.5271/sjweh.3557. https://ec.europa.eu/eurostat/web/main/data/database.

104. Stringhini S, Berkman L, Dugravot A, et al. Socioeconomic status, structural and functional measures of social support, and mortality: the British Whitehall II cohort study, 1985-2009. Am J Epidemiol. 2012;175(12):1275-83.

105. Nyberg ST, Fransson EI, Heikkilä K, et al. Job strain and cardiovascular disease risk factors: Meta-analysis of individual participant data from 47,000 men and women. PLoSOne. 2013;8:e67323. doi:10.1371/journal.pone.0067323.

106. Котова М. Б., Розанов В. Б., Александров А. А. и др. Ассоциация психосоциального стресса с социально-пси хологической средой, образом жизни и факторами риска CCЗ у мужчин среднего возраста, проживающих в г. Москве. Российский кардиологический журнал. 2021;26(5):4335. doi:10.15829/1560-4071-2021- 4335.

107. Sumner JA, Kubzansky LD, Elkind MSV, et al. Trauma Exposure and Posttraumatic Stress Disorder Symptoms Predict Onset of Cardiovascular Events in Women. Circulation. 2015;132(4):251-9.

108. Khalatbari-Soltani S, Stanaway F, Cvejic E, et al. Contribution of psychosocial factors to socioeconomic inequalities in mortality among older Australian men: a population-based cohort study. Int J Equity Health. 2020;19(1):177. doi:10.1186/s12939-020-01277-2.

109. Barth J, Schneider S, von Känel R. Lack of social support in the etiology and the prognosis of coronary heart disease: a systematic review and meta-analysis. Psychosom Med. 2010;72(3):229-38. doi:10.1097/PSY.0b013e3181d01611.

110. Silarova B, Nagyova I, Rosenberger J, et al. Sense of coherence as a mediator between hostility and health-related quality of life among coronary heart disease patients. Heart & Lung. 2016;45(2):126-31. doi:10.1016/j.hrtlng.2015.11.004.

111. Iribarren С, Jacobs DR, Kiefe CI, et al. Causes and demographic, medical, lifestyle and psychosocial predictors of premature mortality: the CARDIA study. Soc Sci Med. 2005;60(3):471-82.

112. Chen H, Zhang B, Xue W, et al. Anger, hostility and risk of stroke: a meta-analysis of cohort studies. J Neurol. 2019;266(4):1016- 26. doi:10.1007/s00415-019-09231-1.

113. Keith F, Krantz DS, Chen R, et al. Anger, hostility, and hospitalizations in patients with heart failure. Health Psychology. 2017;36(9):829-38. doi:10.1037/hea0000519.

114. Smyth A. Physical activity and anger or emotional upset as triggers of acute myocardial infarction: the INTERHEART study. Circulation. 2016;134:1059-67.

115. Peters A, McEwen BS. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139-50. doi:10.1016/j.neubiorev.2015.07.001.

116. Mental health. WHO newsletter dated October 3, 2019. Geneva. WHO. (In Russ.) Психическое здоровье. Информационный бюллетень ВОЗ от 3 октября 2019. Женева. ВОЗ. https://www.who.int/ru/news-room/facts-in-pictures/detail/mental-health.

117. Шальнова С. А., Евстифеева С. Е., Деев А. Д. и др. от имени участников исследования ЭССЕ-РФ. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социально-демографическими факторами (по данным исследования ЭССЕ РФ). Терапевтический архив. 2014;12:52-9. doi:10.17116/terarkh2014861253-60.

118. Евстифеева С. Е., Шальнова С. А., Макарова Ю. К. и др. Ассоциируется ли уровень тревоги и депрессии в по пуляции со смертностью населения? По данным исследова ния ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021;20(5):3009. doi:10.15829/1728-8800-2021-3009.

119. Moise N, Khodneva Y, Jannat-Khah DP, et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. doi:10.1136/bmjopen-2017-017385.

120. Ye S, Muntner P, Shimbo D, et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61:622-30. doi:10.1016/j.jacc.2012.09.058.

121. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77:439-48. doi:10.1016/j.jpsychores.2014.10.001.

122. Holt RI, Phillips DI, Jameson KA, et al. The relationship between depression, anxietyand cardiovascular disease: findings from the HertfordshireCohort Study. J Affect Disord. 2013;150(1):84-90. doi:10.1016/j.jad.2013.02.026.

123. Appels A, Hoppener P, Mulder P. A questionnaire to assess premonitory symptoms of myocardial infarction. Int J Cardiol. 1987;17:15-24. doi:10.1016/0167-5273(87)90029-5.

124. Frestad D, Prescott E. Vital exhaustion and coronary heart disease risk: a systematic review and meta-analysis. Psychosom. Med. 2017;79(3):260-72. doi:10.1097/PSY.0000000000000423.

125. Cohen R, Bavishi C, Haider S, et al. Meta-Analysis of Relation of Vital Exhaustion to Cardiovascular Disease Events. The American journal of cardiology. 2017;119(8):1211-6. doi:10.1016/j.amjcard.2017.01.009.

126. Noser E, Fischer S, Ruppen J, Ehlert U. Psychobiological stress in vital exhaustion. Findings from the Men Stress 40+ study. J Psychosom Res. 2018;105:14-20. doi:10.1016/j.jpsychores.2017.11.019.

127. Balog P, Konkolÿ Thege B. The role of vital exhaustion in predicting the recurrence of vascular events: A longitudinal study. Int J Clin Health Psychol. 2019;19(1):75-9. doi:10.1016/j.ijchp.2018.11.004.

128. Schnohr P, Marott JL, Kristensen TS, et al. Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart Study. European Heart Journal. 2015;36(22):1385. doi:10.1093/eurheartj/ehv027.

129. WHO — Noncommunicable diseases: country profiles 2018, https://www.who.int/publications/i/item/ncd-country-profiles-2018, Последнее обращение: 07.10.2021.

130. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297-305.

131. Шальнова С. А., Деев А. Д., Оганов Р. Г. Факторы, влияющие на смертность от ССЗ в российской популяции. Кардиоваскулярная терапия и профилактика. 2005;4(1):4-9.

132. Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855. doi:10.1136/bmj.j5855. Erratum in: BMJ. 2018;361:k1611. Erratum in: BMJ. 2018;363:k5035.

133. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923-94. doi:10.1016/S0140-6736(18)32225-6. Erratum in: Lancet. 2019;393(10167):132. Erratum in: Lancet. 2019;393(10190):e44.

134. Gupta R, Gupta S, Sharma S, et al. Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data. Nicotine Tob Res. 2019;21(1):25-31. doi:10.1093/ntr/nty002.

135. Middlekauff HR. Cardiovascular impact of electronic-cigarette use. Trends Cardiovasc Med. 2020;30(3):133-40. doi:10.1016/j.tcm.2019.04.006.

136. Marsh S, Aldington S, Shirtcliffe P, et al. Smoking and COPD: What really are the risks? Eur Respir J. 2006 Oct;28(4):883-4. doi: 10.1183/09031936.06.00074806.

137. Lundback, B. Lindberg, A. Lindstrom, M et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies., Respir. Med. 2003;97:115-22.

138. Raad D, Gaddam S, Schunemann HJ, et al. Effects of waterpipe smoking on lung function: a systematic review and metaanalysis. Chest. 2011;139:764-74.

139. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ. 2009;180:814-20.

140. Bowler RP, Hansel NN, Jacobson S, et al, Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. J Gen Intern Med. 2017;32(12):1315-22. doi:10.1007/s11606-017-4150-7.

141. Sohal SS, Eapen MS, Naidu VGM, et al. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette ERJ Open Research. 2019;5:00159-2018. doi:10.1183/23120541.00159-2018.

142. Willsa TA, Paganoa I, Williamsb RJ, et al. E-cigarette use and respiratory disorder in an adult sample. Drug and Alcohol Dependence. 2019;194:363-70. doi:10.1016/j.drugalcdep.2018.10.004.

143. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22):2654-64. doi:10.1001/jama.298.22.2654.

144. López Zubizarreta M, Hernández Mezquita MÁ, Miralles García JM, Barrueco Ferrero M. Tobacco and diabetes: clinical relevance and approach to smoking cessation in diabetic smokers. Endocrinol Diabetes Nutr. 2017;64(4):221-31. English, Spanish. doi:10.1016/j.endinu.2017.02.010.

145. Bott U, Jörgens V, Grüsser M, et al. Predictors of glycaemic control in type 1 diabetic patients after participation in an intensified treatment and teaching programme. Diabet Med. 1994;11(4):362-71. doi:10.1111/j.1464-5491.1994.tb00287.x.

146. Empowering women in the face of the tobacco threat in Europe WHO, 2015. (In Russ.) Расширение прав и возможностей женщин перед лицом табачной угрозы в Европе ВОЗ, 2015. https://www.euro.who.int/__data/assets/pdf_file/0007/313000/EmpowerWomenFacingChallengeTobaccoUse1-ru.pdf.

147. Lv X, Sun J, Bi Y, et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol. 2015;199:106-15.

148. Visser WF, Klerx WN, Cremers HWJM, et al. The Health Risks of Electronic Cigarette Use to Bystanders. Int J Environ Res Public Health. 2019;16(9):1525. doi:10.3390/ijerph16091525.

149. Hess IM, Lachireddy K, Capon A. A systematic review of the health risks from passive exposure to electronic cigarette vapour. Public Health Res Pract. 2016;26(2):2621617. doi:10.17061/phrp2621617.

150. WHO, Global status report on alcohol and health 2018. https://www.who.int/publications/i/item/9789241565639.

151. Rehm J, Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease. Subst Abuse Treat Prev Policy. 2016;11(1):37. doi:10.1186/s13011-016-0081-2.

152. Rehm J, Gmel GE Sr, Gmel G, et al. The relationship between different dimensions of alcohol use and the burden of diseasean update. Addiction. 2017;112(6):968-1001. doi:10.1111/add.13757.

153. Manthey J, Shield KD, Rylett M, et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393(10190):2493-502. doi:10.1016/S0140-6736(18)32744-2.

154. Rehm J, Manthey J, Shield KD, Ferreira-Borges C. Trends in substance use and in the attributable burden of disease and mortality in the WHO European Region, 2010-16. Eur J Public Health. 2019;29(4):723-8. doi:10.1093/eurpub/ckz064.

155. Jasilionis D, Leon DA, Pechholdová M. Impact of alcohol on mortality in Eastern Europe: Trends and policy responses. Drug Alcohol Rev. 2020;39(7):785-9. doi:10.1111/dar.13167.

156. Shield KD, Rehm J. Russia-specific relative risks and their effects on the estimated alcohol-attributable burden of disease. BMC Public Health. 2015;15:482. doi:10.1186/s12889-015-1818-y.

157. Shield K, Manthey J, Rylett M, et al. National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: a comparative risk assessment study. Lancet Public Health. 2020;5(1):e51-e61. doi:10.1016/S2468-2667(19)30231-2.

158. Felson M, Berends R, Richardson B, Veno AE. Reducing pub hopping and related crime, in Policies for Prevention: Reducing Crime. Public Intoxication and Injury. Criminal Justice Press. 1997, pp. 115-132.

159. Mohler-Kuo M, Dowdall GW, Koss M, Wechsler H. Correlates of rape while intoxicated in a national sample of college womenexternal icon. Journal of Studies on Alcohol. 2004;65(1):37-45.

160. Abbey A. Alcohol-related sexual assault: A common problem among college studentsexternal icon. J Stud Alcohol Suppl 2002;14:118-28.

161. Kanny D, Brewer RD, Mesnick JB, et al. Vital Signs: Alcohol Poisoning Deaths — United States, 2010-2012. MMWR. 2015;63:1238-42.

162. Roozen S, Peters GY, Kok G, et al. Systematic literature review on which maternal alcohol behaviours are related to fetal alcohol spectrum disorders (FASD). BMJ Open. 2018;8(12):e022578. doi:10.1136/bmjopen-2018-022578.

163. Rehm J, Baliunas D, Borges GL, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overviewexternal icon. Addiction. 2010;105(5):817-43.

164. Bobak M, Malyutina S, Horvat P, et al. Alcohol, drinking pattern and all-cause, cardiovascular and alcohol-related mortality in Eastern Europe. Eur J Epidemiol. 2016;31(1):21-30. doi:10.1007/s10654-015-0092-8.

165. Connor J. Alcohol consumption as a cause of cancer. Addiction. 2017;112(2):222-8. doi:10.1111/add.13477.

166. Stevens SA, Dudek J, Nash K, et al. Social Perspective Taking and Empathy in Children with Fetal Alcohol Spectrum Disorders. J Int Neuropsychol Soc. 2015;21(1):74-84. doi:10.1017/S1355617714001088.

167. Kendler KS, Lönn SL, Salvatore J, et al. Divorce and the Onset of Alcohol Use Disorder: A Swedish Population-Based Longitudinal Cohort and Co-Relative Study. Am J Psychiatry. 2017;174(5):451-8. doi:10.1176/appi.ajp.2016.16050589.

168. Esser MB, Hedden SL, Kanny D, et al. Prevalence of alcohol dependence among US adult drinkers, 2009-2011. Prev Chronic Dis. 2014;11:E206. doi:10.5888/pcd11.140329.

169. Rehm J, Anderson P, Barry J, et al. Prevalence of and potential influencing factors for alcohol dependence in Europe. Eur Addict Res. 2015;21(1):6-18. doi:10.1159/000365284.

170. Устойчивое здоровое питание. Руководящие принципы. ФАО, ВОЗ. Рим, 2020, 44 с. doi:10.4060/ca6640ru.

171. Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients. 2013;5:3646-83.

172. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;393:1958-72. doi:10.1016/S0140-6736(19)30041-8.

173. World Cancer Research Fund/American Institute for Cancer Research. Third Expert Report Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Continuous Update Project Expert Report 2018. https://www.wcrf.org/dietandcancer.

174. Wei H, Gao Z, Liang R, et al. Whole-grain consumption and the risk of all-cause, CVD and cancer mortality: a meta-analysis of prospective cohort studies. Br J Nutr. 2016;116(3):514-25. doi:10.1017/S0007114516001975.

175. Marventano S, Pulido MI, Sánchez-González C, et al. Legume consumption and CVD risk: a systematic review and metaanalysis. Public Health Nutr. 2017;20(2):245-54. doi:10.1017/S1368980016002299.

176. Viguiliouk E, Glenn AJ, Nishi SK, et al. Associations between Dietary Pulses Alone or 9with Other Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Adv Nutr. 2019;10(4):308-19. doi:10.1093/advances/nmz113.

177. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67. doi:10.1016/j.jacc.2011.06.063.

178. Van Dael P. Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendations. Nutr Res Pract. 2021;15(2):137-59. doi:10.4162/nrp.2021.15.2.137.

179. de Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies. BMJ. 2015;351:h3978. doi:10.1136/bmj.h3978.

180. Ricci C, Baumgartner J, Zec M, et al. Type of dietary fat intakes in relation to all-cause and cause-specific mortality in US adults: An iso-energetic substitution analysis from the American National Health and Nutrition Examination Survey linked to the US mortality registry. Br J Nutr. 2018;119:456-63. doi:10.1017/S0007114517003889.

181. Zhang B, Xiong K, Cai J, Ma A. Fish Consumption and Coronary Heart Disease: A Meta-Analysis. Nutrients. 2020;12(8):2278. doi:10.3390/nu12082278.

182. Yu XF, Zou J, Dong J. Fish consumption and risk of gastrointestinal cancers: a meta-analysis of cohort studies. World J Gastroenterol. 2014;20(41):15398-412. doi:10.3748/wjg.v20.i41.15398.

183. Cancer: Carcinogenicity of the consumption of red meat and processed meat. 2015. https://www.who.int/news-room/questions-and-answers/item/cancer-carcinogenicity-of-theconsumption-of-red-meat-and-processed-meat.

184. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009;23(6):363-84. doi:10.1038/jhh.2008.144.

185. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624-34. doi:10.1056/NEJMoa1304127.

186. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101.

187. Malik VS, Pan A, Willett WC, et al. Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. Am J Clin Nutr. 2013;98(4):1084-102. doi:10.3945/ajcn.113.058362.

188. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. Edited by Bruno de Benoist, Erin McLean, Ines Egli and Mary Cogswell. WHO, 2020. ISBN: 978924159665 7

189. Здоровое питание матери: лучшее начало жизни. ВОЗ, 2016. https://www.euro.who.int/ru/publications/abstracts/good-maternal-nutrition.-the-best-start-in-life-2016.

190. Minimum dietary diversity for women. FAO. 2021. Rome. 176р. doi:10.4060/cb3434en

191. Physical Activity Guidelines for Americans 2nd edition. US Department of Health and Human Services. 2018. Accessed July 21, 2019. health.gov/pagui delin es/second-editi on/pdf/Physical_Activ ity_Guide lines_2nd_editi on.pdf

192. Карамнова Н. С., Шальнова С. А., Деев А. Д. и др. от имени участников исследования ЭССЕРФ. Характер питания взрослого населения по данным эпидемиологического исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2018;17(4):61-6. doi:10.15829/1728-8800-2018-4-61-66.

193. Баланова Ю. А., Концевая А. В., Шальнова С. А., и др. от имени участников исследования ЭССЕ-РФ. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина. 2014; 5:42-52.

194. Карамнова Н. С., Максимов С. А., Шальнова С. А. и др. Кардиопротективный тип питания: распространенность, ассоциации и резервы профилактики. Российский кардиологический журнал. 2020;25(6):3769. doi:10.15829/1560-4071-2020-3769.

195. Борьба с неинфекционными заболеваниями: решения, оптимальные по затратам и другие рекомендуемые мероприятия по профилактике неинфекционных заболеваний и борьбе с ними. Женева: ВОЗ, 2017. https://apps.who.int/iris/handle/10665/259464.

196. Глобальный план действий ВОЗпо повышению уровня физической активности на 2018-2030гг. Повышение уровня активности людей для укрепления здоровья в мире. https://apps.who.int/iris/bitstream/handle/10665/279655/WHO-NMH-PND-18.5-rus.pdf?ua=1.

197. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-62. doi:10.1136/bjsports-2020-102955.

198. Marijon E, Tafflet M, Celermajer DS, et al. Sports related sudden death in the general population. Circulation. 2011;124:672-81.

199. Lollgen H, Bockenhoff A, Knapp G. Physical activity and allcause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med. 2009;30:213-24.

200. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873-934.

201. Kontsevaya A, Shalnova S, Deev A, et al. Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obes Facts. 2019;12(1):103-14. doi:10.1159/000493885.

202. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. Eur J Epidemiol. 2013;28:513-23.

203. Драпкина О. М., Карамнова Н. С., Концевая А. В. и др. РОПНИЗ. Алиментарно-зависимые факторы риска хронических неинфекционных заболеваний и привычки питания: диетологическая коррекция в рамках профилактического консультирования. Методические рекомендации. Кардиоваскулярная терапия и профилактика. 2021;20(5):2952. doi:10.15829/1728-8800-2021-2952.

204. Дедов И. И., Шестакова М. В., Галстян Г. Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12. doi:10.14341/DM2004116-17.

205. Cruz-Jentoft AJ, Bahat G, Bauer J. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.

206. Kennedy O, Su F, Pears R, et al. Evaluating the effectiveness of the NHS Health Check programme in South England: a quasirandomised controlled trial. BMJ Open. 2019;9:e029420.

207. Шляхто Е. В., Недогода С. В., Конради А. О. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). СПб. 2017. c. 164.

208. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018;71(1):69-84. doi:10.1016/j.jacc.2017.11.011.

209. Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92:266-79.

210. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-95. doi:10.1016/S0140-6736(11)60105-0.

211. Aune D, Sen A, Prasad M. BMI and all cause mortality: systematic review and non-linear dose-response. Meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.

212. Sun YQ, Burgess S, Staley JR. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ 2019;364:l1042.

213. Lamelas PM, Maheer K, Schwalm JD. Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis. Acta Cardiol. 2017;72:655-61.

214. Mahajan R, Stokes M, Elliott A. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart. 2020;106:58-68.

215. Prado CM, Gonzalez MC, Heymsfield SB. Bodycomposition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care. 2015;18:535-51.

216. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1):40-66. doi:10.1159/000496183.

217. Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249-58.

218. Neeland IJ, Ross R, Després JP, et al.; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;(9):715-25.

219. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.

220. Bell JA, Hamer M, Sabia S. The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65:101-2.

221. Magkos F. Metabolically healthy obesity: what’s in a name? Am J Clin Nutr. 2019;110(3):533-9.

222. Lavie CJ, Laddu D, Arena R. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol.2018;72(13):1506-31.

223. Liu C, Wang C, Guan S, et al. The prevalence of metabolically healthy and unhealthy obesity according to different criteria. Obes Facts. 2019;12(1):78-90.

224. Blüher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41(3):bnaa004. doi:10.1210/endrev/bnaa004.

225. Dicker D, Bettini S, Farpour-Lambert N, et al. Obesity and COVID-19: The Two Sides of the Coin. Obes Facts. 2020;13:430-8. doi:10.1159/000510005.

226. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142(1):68-78.

227. Sattar N, McInnes IB, McMurray JJ. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;142(1):4-6.

228. Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13(8):707-12.

229. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-51.

230. Simonnet A, Chetboun M, Poissy J. COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-9.

231. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular dis ease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-72.20.

232. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.

233. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90.

234. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.

235. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36:539-50.

236. HPS3/TIMI55-REVEAL Collaborative Group Bowman L, Hopewell JC, Chen F, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377:1217-27.

237. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med. 2013;173:664-71.

238. Kooter AJ, Kostense PJ, Groenewold J, et al. Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741-5.

239. Дедов И. И., Шестакова М. В., Майоров А. Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 10-й выпуск. Москва, 2021. doi:10.14341/DM12802.

240. Федеральный регистр больных с сахарным диабетом. http://sd.diaregistry.ru/

241. Мкртумян А. М. Уровень гликемии как фактор риска сердечно-сосудистых заболеваний. Сахарный диабет. 2010;13(3):80-2. doi:10.14341/2072-0351-5493.

242. Nasri H, Rafieian-Kopae M. Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci. 2015;20(11):1112-20. doi:10.4103/1735-1995.172845.

243. Попыхова Э. Б., Степанова Т. В., Лагутина Д. Д. и др. Роль сахарного диабета в возникновении и развитии эндотелиальной дисфункции. Проблемы эндокринологии. 2020;66(1):47-55. doi:10.14341/probl12212.

244. Balkau B, Shipley M, Jarret RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21(3):360-7. doi:10.2337/diacare.21.3.360.

245. Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. doi:10.1016/S0140-6736(10)60484-9.

246. Pechlivani N., Ramzi A. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. Front Cardiovasc Med. 2018;5:1. doi:10.3389/fcvm.2018.00001.

247. Ajjan Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a metaanalysis. Osteoporos Int. 2007;18(4):427-44. doi:10.1007/s00198-006-0253-4.

248. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes. 2011;2(3):41-8. doi:10.4239/wjd.v2.i3.41.

249. Nguyen JL, Yang W, Ito K, et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1(3):274-81. doi:10.1001/jamacardio.2016.0433.

250. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. New England Journal of Medicine. 2018;378(4):345-53. doi:10.1056/NEJMoa1702090.

251. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-8.

252. Chow EJ, O’Halloran A, Rolfes MA, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults. Ann Intern Med. 2021;174(4):583-4. doi:10.7326/L21-0018.

253. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010;182:1617-23.

254. Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine. 2011;29:1145-9.

255. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. European Heart Journal. 2009;30:209-16.

256. Бойцов С. А., Лукьянов М. М., Платонова Е. В., и др. Оценка эффективности вакцинопрофилактики гриппа по данным проспективного контроля у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения. Рациональная фармакотерапия в кардиологии. 2016;12(6):703-10. doi:10.20996/1819-6446-2016-12-6-703-710.

257. Pankayatselvan V, Mukamal KJ. Influenza Vaccination Among Adults with Cardiovascular Disease in the United States: Results from the Behavioral Risk Factor Surveillance System 2018-2019. Am Heart J. 2022;244:50-3. doi:10.1016/j.ahj.2021.09.004.

258. Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям. Минздрав РФ. Приказ от 21 марта 2014 г. N 125н. https://base.garant.ru/70647158.

259. Драпкина О. М., Брико Н. И., Костинов М. П. и др. Иммунизация взрослых. Методические рекомендации. М., ФГБУ “НМИЦ ТПМ” Минздрава России: 2020. 248 с.

260. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;2013(1):CD000422. doi:10.1002/14651858.CD000422.pub3.

261. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014;58(3):309-18. doi:10.1093/cid/cit816.

262. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81.

263. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res. 2012;110:658-62.

264. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-20.

265. Гуманова Н. Г. Аналитический комплекс биохимических маркеров для доклинической диагностики и профилактики сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2019;18(5):117-27.

266. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146-56.

267. Ezhov MV, Shalnova SA. Yarovaya EB, et al. Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases. Arch Med Sci. 2021. doi:10.5114/aoms/131089.

268. Yeang C, Witztum JL, Tsimikas S. ‘LDL-C’=LDL-C+Lp(a)-C: implications of achieved ultra-low LDL-C levels in the pro protein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26:169-78.

269. Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol. 2017;70:558-68.

270. Шальнова С. А., Драпкина О. М., Концевая А. В. и др. Пилотный проект по изучению ассоциации тропонина I с сердечно-сосудистыми осложнениями в популяции российского региона. Кардиовасулярная терапия и профилактика. 2021;20(5):185-92.

271. Willeit P, Kaptoge S, Welsh P, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2016;4:840-9.

272. Метельская В. А., Гуманова Н. Г. Валидные кардиоспецифические биохимические маркеры. Часть I. Кардиоваскулярная терапия и профилактика. 2020;19(4):2573.

273. Гуманова Н. Г., Климушина М. В., Богданова Н. Л. и др.. Валидные кардиоспецифические биохимические маркеры. Часть II. Кардиоваскулярная терапия и профилактика. 2020;19(5):2588.

274. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78.

275. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907.

276. Saridemir S, Güven HE, Aksel B, Doğan L. Serum AMDL DR-70 levels: a new concept in the diagnosis and follow-up of colorectal carcinoma. Biomark Med. 2020;14(8):621-8. doi:10.2217/bmm-2020-0004.

277. Dochez V, Caillon H, Vaucel E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. doi:10.1186/s13048-019-0503-7.

278. Zhang Z. An in Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers. Rev Obstet Gynecol. 2012;5(1):35-41.

279. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313(1-2):15-9. doi:10.1016/s0009-8981(01)00644-1.

280. Jayaraman S, Chittiboyina S, Bai Y, et al. The nuclear mitotic apparatus protein NuMA controls rDNA transcription and mediates the nucleolar stress response in a p53-independent manner. Nucleic Acids Res. 2017;45(20):11725-42. doi:10.1093/nar/gkx782.

281. Miller BE, Tal-Singer R, Rennard SI, et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;193(6):607-13. doi:10.1164/rccm.201509-1722PP.

282. Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breath. 2019;15(4):296-304. doi:10.1183/20734735.0258-2019.

283. Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart. 2010;96:1985-9.

284. Gray B, Semsarian C. Genetic Testing for Inherited Cardiovascular Disease: Implications of the AHA Scientific Statement for Cardiologists. Heart Lung Circ. 2020;29(11):1581-4. doi:10.1016/j.hlc.2020.09.001.

285. Roberts R, Fair J. A Less than Provocative Approach for the Primary Prevention of CAD. J Cardiovasc Transl Res. 2021. doi: 10.1007/s12265-021-10144-6. Epub ahead of print.

286. Roberts R, Chang CC, Hadley T. Genetic Risk Stratification: A Paradigm Shift in Prevention of Coronary Artery Disease. JACC Basic Transl Sci. 2021;6(3):287-304. doi:10.1016/j.jacbts.2020.09.004.

287. Мешков А. Н., Щербакова Н. В. Молекулярно-генетическая диагностика предрасположенности к развитию ишемической болезни сердца: современное состояние проблемы. Consilium Medicum. 2016;18(12):22-6.

288. Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475.

289. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: A comprehensive review. C R Biol. 2017;340(2):87-108. doi:10.1016/j.crvi.2016.11.007.

290. Bishay RH, Greenfield JR. A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. Med J Aust. 2016;205(10):480-5. doi:10.5694/mja16.00458.

291. Naylor R, Knight Johnson A, del Gaudio D. Maturity-Onset Diabetes of the Young Overview. 2018 May 24. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022.

292. Arnold N, Koenig W. Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from LipidLowering Therapy? Cardiovasc Drugs Ther. 2021;35(3):627-35. doi:10.1007/s10557-020-07105-7.

293. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-24. doi:10.1038/s41588-018-0183-z.

294. Khera AV, Chaffin M, Zekavat SM, et al. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. Circulation. 2019;139(13):1593-602. doi:10.1161/CIRCULATIONAHA.118.035658.

295. Bensenor IM, Goulart AC, Santos IS, et al. Association between a healthy cardiovascular risk factor profile and coronary artery calcium score: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Am Heart J. 2016;174:51-9. doi:10.1016/j.ahj.2015.12.018.

296. Tikkanen E, Havulinna AS, Palotie A, et al. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(9):2261-6. doi:10.1161/ATVBAHA.112.301120.

297. Ganna A, Magnusson PK, Pedersen NL, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33(9):2267-72. doi:10.1161/ATVBAHA.113.301218.

298. Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart disease. Eur Heart J. 2016;37(43):3267-78. doi:10.1093/eurheartj/ehw450.

299. Elliott J, Bodinier B, Bond TA, et al. Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease. JAMA. 2020;323(7):636-45. doi:10.1001/jama.2019.22241.

300. Inouye M, Abraham G, Nelson CP, et al.; UK Biobank CardioMetabolic Consortium CHD Working Group. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018;72(16):1883-93. doi:10.1016/j.jacc.2018.07.079.

301. Agbaedeng TA, Noubiap JJ, Mofo Mato EP, et al. Polygenic risk score and coronary artery disease: A meta-analysis of 979,286 participant data. Atherosclerosis. 2021;333:48-55. doi:10.1016/j.atherosclerosis.2021.08.020.

302. Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349-58. doi:10.1056/NEJMoa1605086.

303. Iribarren C, Lu M, Jorgenson E, et al. Clinical Utility of Multimarker Genetic Risk Scores for Prediction of Incident Coronary Heart Disease: A Cohort Study Among Over 51 000 Individuals of European Ancestry. Circ Cardiovasc Genet. 2016;9(6):531-40. doi:10.1161/CIRCGENETICS.116.001522. Erratum in: Circ Cardiovasc Genet. 2017;10(2). Title corrected.

304. Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264-71. doi:10.1016/S0140-6736(14)61730-X.

305. Kullo IJ, Jouni H, Austin EE, et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation. 2016;133(12):1181-8. doi:10.1161/CIRCULATIONAHA.115.020109.

306. Fava C, Sjögren M, Montagnana M, et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension. 2013;61(2):319- 26. doi:10.1161/HYPERTENSIONAHA.112.202655. Erratum in: Hypertension. 2013;61(5):e50.

307. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Million Veteran Program. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412-25. doi:10.1038/s41588-018-0205-x. Erratum in: Nat Genet. 2018;50(12):1755.

308. Giontella A, Sjögren M, Lotta LA, et al. Clinical Evaluation of the Polygenetic Background of Blood Pressure in the PopulationBased Setting. Hypertension. 2021;77(1):169-77. doi:10.1161/HYPERTENSIONAHA.120.15449.

309. Ibrahim-Verbaas CA, Fornage M, Bis JC, et al. Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke. 2014;45(2):403-12. doi:10.1161/STROKEAHA.113.003044.

310. Li J, Chaudhary DP, Khan A, et al. Polygenic Risk Scores Augment Stroke Subtyping. Neurol Genet. 2021;7(2):e560. doi:10.1212/NXG.0000000000000560.

311. Muiño E, Krupinski J, Carrera C, et al. An Inflammatory Polymorphisms Risk Scoring System for the Differentiation of Ischemic Stroke Subtypes. Mediators Inflamm. 2015;2015:569714. doi:10.1155/2015/569714.

312. Hachiya T, Kamatani Y, Takahashi A, et al. Genetic Predisposition to Ischemic Stroke: A Polygenic Risk Score. Stroke. 2017;48(2):253-8. doi:10.1161/STROKEAHA.116.014506.

313. Jung KJ, Hwang S, Lee S, Kim HC, Jee SH. Traditional and Genetic Risk Score and Stroke Risk Prediction in Korea. Korean Circ J. 2018;48(8):731-40. doi:10.4070/kcj.2018.0036.

314. Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 2019;177(3):587-96.e9. doi:10.1016/j.cell.2019.03.028.

315. Liu W, Zhuang Z, Wang W, et al. An Improved Genome-Wide Polygenic Score Model for Predicting the Risk of Type 2 Diabetes. Frontiers in genetics. 2021;12:63. doi:10.3389/fgene.2021.632385.

316. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50(11):1505-13. doi:10.1038/s41588-018-0241-6.

317. Vujkovic M, Keaton JM, Lynch JA, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52(7):680-91. doi:10.1038/s41588-020-0637-y.

318. Moldovan A, Waldman YY, Brandes N, et al. Body Mass Index and Birth Weight Improve Polygenic Risk Score for Type 2 Diabetes. J Pers Med. 2021;11(6):582. doi:10.3390/jpm11060582.

319. Chen X, Liu C, Si S, et al. Genomic risk score provides predictive performance for type 2 diabetes in the UK biobank. Acta Diabetol. 2021;58(4):467-74. doi:10.1007/s00592-020-01650-1.

320. Ye Y, Chen X, Han J, et al. Interactions Between Enhanced Polygenic Risk Scores and Lifestyle for Cardiovascular Disease, Diabetes, and Lipid Levels. Circ Genom Precis Med. 2021;14(1):e003128. doi:10.1161/CIRCGEN.120.003128.

321. Hardy DS, Racette SB, Garvin JT, et al. Ancestry specific associations of a genetic risk score, dietary patterns and metabolic syndrome: a longitudinal ARIC study. BMC Med Genomics. 2021;14:118. doi:10.1186/s12920-021-00961-8.

322. Aric Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687-702.

323. WHO. Saving Lives, Spending Less: A Strategic Response to Noncommunicable Diseases. Geneva: World Health Organization, 2018.

324. Decree of the President of the Russian Federation dated 07.05.2018 No. 204 “On National Goals and Strategic Objectives of the Development of the Russian Federation for the period up to 2024”. (In Russ.) Указ Президента РФ от 07.05.2018 г. № 204 “О национальных целях и стратегических задачах развития Российской Федерации на период до 2024 года”. http://www.kremlin.ru/acts/bank/43027.

325. Паспорт федерального проекта “Формирование системы мотивации граждан к здоровому образу жизни, включая здоровое питание и отказ от вредных привычек”. https://static-1.rosminzdrav.ru/system/attachments/attaches/000/047/184/original/паспортФПУкрепление_общественного_здоровья.pdf?1567700975.

326. WHO. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva: Word Health Organization, 2013.

327. Распоряжение Правительства РФ от 18 ноября 2019 г. № 2732-р “О Концепции осуществления государственной политики противодействия потреблению табака и иной никотинсодержащей продукции в РФ на период до 2035 г. и дальнейшую перспективу”. https://www.garant.ru/products/ipo/prime/doc/72943536.

328. Распоряжение Правительства РФ от 30 апреля 2021 года №1151-р “План мероприятий по реализации Концепции осуществления государственной политики противодействия потреблению табака и иной никотинсодержащей продукции в Российской Федерации на период до 2035 года и дальнейшую перспективу”. http://static.government.ru/media/files/bpG6BAI2ud92bfxPEiXMe5Mbl3cAAhzf.pdf.

329. Письмо МЗ РФ от 12.11.2019г. № 28-1/6419 “Рекомендации по созданию региональных и муниципальных программ укрепления здоровья” (федеральный проект “Укрепление общественного здоровья” национальный проект “Демография”), МЗ РФ, Москва 2019.

330. Приказ Минздрава РФ от 27 апреля 2021 г. N 404н “Об утверждении Порядка проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения”. http://www.garant.ru/hotlaw/federal/1471241.

331. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439-54.

332. Chamnan P, Simmons RK, Khaw KT, et al. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ. 2010;340:c1693.

333. Adherence to long-term therapies Project: evidence for action WHO. Geneva, Switzerland. 2003. 211 р. ISBN 9241545992. https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.

334. Маслоу А. Г. Мотивация и личность. 3-изд. Пер. с англ. СПб: Питер, 2009. 352 с.

335. Миллер УР, Роллник С. Мотивационное консультирование: как помочь людям измениться. М: ООО “Издательство “Э”, 2017. 360 с.

336. Калинина А. М. Концептуальная основа профилактического консультирования пациентов с хроническими неинфекционными заболеваниями и факторами риска их развития. Кардиоваскулярная терапия и профилактика, 2012;11(4) 4-9.

337. Роджерс К. Р. Консультирование и психотерапия. Новейшие подходы в области практической работы: монография. Пер. с англ. Кондрашовой О., Кучкаревой Р. Ред. Гришпун И., Бобко С., Ряшина В. М.: Изд-во ЭКМОПресс 2000, 464 с.

338. Prochaska JO, DiClemente СС. Transtheoretical therapy: Toward a more integrative model of change. Psychotherapy. Theory, Research and Practice. 1982;19:276-88.

339. WHO. Healthy diet. Fact sheets. WHO, 29 April 2020. https://www.who.int/ru/news-room/fact-sheets/detail/healthy-diet.

340. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения российской Федерации. Методические рекомендации МР 2.3.1.0253-21. Москва, 2021. (утв. Федеральной службой по надзору в сфере защиты прав потребителей и благополучия человека 22 июля 2021 г. http://www.garant.ru/products/ipo/prime/doc/402716140/#ixzz78APSyaZH.

341. Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, et al. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. Adv Nutr. 2019;10(suppl 1):S17-S30.

342. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879.

343. Zhang Z, Xu G, Liu D, et al. Dietary fiber consumption and risk of stroke. Eur J Epidemiol. 2013;28:119-30.

344. Yao B, Fang H, Xu W, et al. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol. 2014;29:79-88.

345. Giacco R, Costabile G, Della Pepa G, et al. A whole-grain cerealbased diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab Cardiovasc Dis. 2014;24:837-44.

346. Globalization, diets and noncommunicable diseases. Geneva, World Health Organization, 2002. http://whqlibdoc.who.int/publications/9241590416.pdf (22 June 2021).

347. Robertson A, Tirado C, Lobstein T, et al. Food and health in Europe: a new basis for action. WHO Reg Publ Eur Ser. 2004;(96):i-xvi, 1-385, back cover.

348. WHO. Guideline: Sugars intake for adults and children. Published 2015. https://www.who.int/publications/i/item/9789241549028.

349. Yang Q, Zhang Z, Gregg EW, et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. 2014;174:516-24.

350. Mullee A, Romaguera D, Pearson-Stuttard J, et al. Association Between Soft Drink Consumption and Mortality in 10 European Countries. JAMA Intern Med. 2019;179:1479-90.

351. He FJ, Tan M, Ma Y, et al. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol, 2020;75:632-47.

352. Selmer RM, Kristiansen IS, Haglerod A, et al. Cost and health consequences of reducing the population intake of salt. J Epidemiol Community Health. 2000;54(9):697-702. doi:10.1136/jech.54.9.697.

353. Официальный сайт Федеральной службы государственной статистики. Итоги “Выборочного наблюдения рациона питания населения”. https://rosstat.gov.ru/itog_inspect.

354. Guideline: Sodium intake for adults and children. Geneva: World Health Organization, 2012.

355. Guideline: Potassium intake for adults and children. Geneva: World Health Organization, 2012.

356. Schöttker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656. doi:10.1136/bmj.g3656.

357. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490.

358. Schwingshackl L, Schwedhelm C, Hoffmann G, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2017;105(6):1462-73. doi:10.3945/ajcn.117.153148.

359. Zurbau A, Au-Yeung F, Mejia SB, et al. Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2020;9(19):e017728. doi:10.1161/JAHA.120.017728.

360. Hu D, Huang J, Wang Y, et al. Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies. Stroke. 2014;45(6):1613-9. doi:10.1161/STROKEAHA.114.004836.

361. Mihrshahi S, Dobson AJ, Mishra GD. Fruit and vegetable consumption and prevalence and incidence of depressive symptoms in mid-age women: results from the Australian longitudinal study on women’s health. Eur J Clin Nutr. 2015;69(5):585-91. doi:10.1038/ejcn.2014.222.

362. Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100(1):256-69. doi:10.3945/ajcn.113.076109.

363. Afshin A, Micha R, Khatibzadeh S, et al. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100:278-88.

364. Gaesser GA. Whole Grains, Refined Grains, and Cancer Risk: A Systematic Review of Meta-Analyses of Observational Studies. Nutrients. 2020;12(12):3756. doi:10.3390/nu12123756.

365. Schwingshackl L, Schwedhelm C, Hoffmann G, et al. Food groups and risk of colorectal cancer. Int J Cancer. 2018;142:1748-58.

366. Zeraatkar D, Johnston BC, Bartoszko J, et al. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. Ann Intern Med. 2019;171:721-31.

367. Chowdhury R, Stevens S, Gorman D, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ. 2012;345:e6698. doi:10.1136/bmj.e6698.

368. Tverdal A, Selmer R, Cohen JM, Thelle DS. Coffee consumption and mortality from cardiovascular diseases and total mortality: Does the brewing method matter? Eur J Prev Cardiol. 2020;27:1986-93.

369. Погожева А. В., Дербенева С. А. Оценка эффективности применения продукта, обогащенного фитостеринами, в диетотерапии больных сердечно-сосудистыми заболеваниями. Кардиология. 2008,9:47-9.

370. Schwingshackl L, Schwedhelm C, Galbete C, Hoffmann G. Adherence to Mediterranean diet and risk of Cancer: an updated systematic review and meta-analysis. Nutrients. 2017;9(10):1063. doi:10.3390/nu9101063.

371. Andreu-Reinón ME, Chirlaque MD, Gavrila D, et al. Mediterranean Diet and Risk of Dementia and Alzheimer’s Disease in the EPIC-Spain Dementia Cohort Study. Nutrients. 2021;13(2):700. doi:10.3390/nu13020700.

372. Lacoppidan SA, Kyrø C, Loft S, et al. Adherence to a Healthy Nordic Food Index Is Associated with a Lower Risk of Type-2 Diabetes-The Danish Diet, Cancer and Health Cohort Study. Nutrients. 2015;7(10):8633-44. doi:10.3390/nu7105418.

373. Hansen CP, Overvad K, Kyrø C, et al. Adherence to a Healthy Nordic Diet and Risk of Stroke: A Danish Cohort Study. Stroke. 2017;48(2):259-64. doi:10.1161/STROKEAHA.116.015019.

374. Adamsson V, Reumark A, Fredriksson IB, et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). J Intern Med. 2011;269(2):150-9. doi:10.1111/j.1365-2796.2010.02290.x.

375. Tertsunen HM, Hantunen S, Tuomainen TP, Virtanen JK. Healthy Nordic diet and risk of disease death among men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Nutr. 2020;59(8):3545-53. doi:10.1007/s00394-020-02188-2.

376. Grosso G, Bella F, Godos J, et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr Rev. 2017;75:405-19.

377. Steck SE, Guinter M, Zheng J, Thomson CA. Index-based dietary patterns and colorectal cancer risk: a systematic review. Adv Nutr. 2015;6(6):763-73. doi:10.3945/an.115.009746.

378. Wang F, Zheng J, Yang B, et al. Effects of Vegetarian Diets on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(10):e002408. doi:10.1161/JAHA.115.002408.

379. Yokoyama Y, Levin SM, Barnard ND. Association between plantbased diets and plasma lipids: a systematic review and metaanalysis. Nutr Rev. 2017;75(9):683-98. doi:10.1093/nutrit/nux030.

380. Heffron SP, Parham JS, Pendse J, Alemán JO. Treatment of Obesity in Mitigating Metabolic Risk. Circ Res. 2020;126(11):1646-65. doi:10.1161/CIRCRESAHA.119.315897. Erratum in: Circ Res. 2020;127(2):e79.

381. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension. 2016;67:733-9. doi:10.1161/HYPERTENSIONAHA.115.06853.

382. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591-601. doi:10.1016/j.cmet.2016.02.005.

383. Freire R. Scientific evidence of diets for weight loss: Different macronutrient composition, intermittent fasting, and popular diets. Nutrition. 2020;69:110549. doi:10.1016/j.nut.2019.07.001.

384. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss. Am J Med. 2016;129:407-15e404.

385. Anton SD, Moehl K, Donahoo WT, et al. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring). 2018;26(2):254-68. doi:10.1002/oby.22065.

386. Raynor HA, Champagne CM. Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. J Acad Nutr Diet. 2016;116(1):129-47. doi:10.1016/j.jand.2015.10.031.

387. Ge L, Sadeghirad B, Ball GDC. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomized trials. BMJ. 2020;369:m696.

388. Reynolds A, Mann J, Cummings J. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 2019;393:434-445

389. Kirkpatrick CF, Bolick JP, Kris-Etherton PM. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol 2019;13:689-711e681.

390. Rynders CA, Thomas EA, Zaman A. Effectiveness of Intermittent Fasting and Time-Restricted Feeding Compared to Continuous Energy Restriction for Weight Loss. Nutrients 2019;11:2442.

391. Клинические рекомендации: Лечение ожирения у взрослых. Российская Ассоциация Эндокринологов. 2019. https://cr.minzdrav.gov.ru.

392. Yumuk V, Tsigos C, Fried M, et al.; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-24. doi:10.1159/000442721. Erratum in: Obes Facts. 2016;9(1):64.

393. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707.

394. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-34. doi:10.1001/jama.2016.7602. Erratum in: JAMA. 2016;316(9):995.

395. Мельниченко Г. А., Романцова Т. И., Журавлева М. В. Всероссийская программа безопасного снижения веса “ПримаВера”. Итоги первого года проведения. Ожирение и метаболизм. 2014;(1):62-8. doi:10.14341/omet2014162-68.

396. Трошина Е. А., Ершова Е. В. Фармакотерапия ожирения: что нового? Проблемы Эндокринологии. 2018;64(4):270-6. doi:10.14341/probl9315.

397. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр. Ожирение и метаболизм. 2018;15(1):53-70. doi:10.14341/OMET2018153-70.

398. Taylor DHJr, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity. Am. J. Public Health. 2002;92:990-6.

399. van Schayck CP, Kaper J. Smoking and COPD: will they ever vanish into smoke? (Editorial). Primary Care Respir. J. 2006;15:81-3.

400. Anthonisen NR, Skeans MA, Wise RA, et al. The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. A Randomized Clinical Trial. Ann. Intern. Med. 2005;142:233-9.

401. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309(10):1014-21. doi:10.1001/jama.2013.1644.

402. Hu Y, Zong G, Liu G, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med. 2018;379:623-32.

403. Global Strategy for the diagnosis, management and prevention of COPD, 2021. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.

404. Borland R, Yong HH, O’Connor RJ, et al. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. Nicotine Tob Res. 2010;12 Suppl(Suppl 1): S45-50. doi:10.1093/ntr/ntq038.

405. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146.

406. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016:CD006103.

407. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. doi:10.1002/14651858.CD000146.pub4. Update in: Cochrane Database Syst Rev. 2018;5:CD000146.

408. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329. doi:10.1002/14651858.CD009329.

409. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4:CD013308.

410. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968_970.

411. Suissa K, Lariviere J, Eisenberg MJ, et al. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials., Circ Cardiovasc Qual Outcomes. 2017;10:e002458.

412. Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018;178:622-31.

413. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;(4):CD006103. doi:10.1002/14651858.CD006103.pub6. Update in: Cochrane Database Syst Rev. 2016;(5):CD006103.

414. Karnieg T, Wang X. Cytisine for smoking cessation. CMAJ. 2018;190:E596.

415. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax. 2013;68:1037.

416. Hajek P, Phillips-Waller A, Przulj D, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med. 2019;380:629-37.

417. Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2020;10:CD010216.

418. Kavousi M, Pisinger C, Barthelemy JC, et al. Electronic cigarettes and health with special focus on cardiovascular effects:, position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2020:2047487320941993.

419. European Heart Network. Electronic cigarettes and cardiovascular disease _ an update from the European Heart Network http://www.ehnheart.org/component/attachments/attachments.html?task=attachment&id=3093 (21 July 2020).

420. Anderson P, Chisholm D, Fuhr DC. Effectiveness and costeffectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet. 2009;373(9682):2234-46. doi:10.1016/S0140-6736(09)60744-3.

421. Foxcroft DR, Tsertsvadze A. Universal school-based prevention programs for alcohol misuse in young people. Cochrane Database Syst Rev. 2011;(5):CD009113. doi:10.1002/14651858.CD009113.

422. Foxcroft DR, Moreira MT, Almeida Santimano NM, Smith LA. Social norms information for alcohol misuse in university and college students. Cochrane Database Syst Rev. 2015;1:CD006748. doi:10.1002/14651858.CD006748.pub3. Update in: Cochrane Database Syst Rev. 2015;12:CD006748.

423. Barata IA, Shandro JR, Montgomery M, et al. Effectiveness of SBIRT for Alcohol Use Disorders in the Emergency Department: A Systematic Review. West J Emerg Med. 2017;18(6):1143-52. doi:10.5811/westjem.2017.7.34373.

424. Schmidt CS, Schulte B, Seo HN, et al. Meta-analysis on the effectiveness of alcohol screening with brief interventions for patients in emergency care settings. Addiction. 2016;111(5):783-94. doi:10.1111/add.13263.

425. McCambridge J, Saitz R. Rethinking brief interventions for alcohol in general practice. BMJ. 2017;356:j116. doi:10.1136/bmj.j116.

426. Драпкина О.М., Дроздова Л.Ю., Калинина А.М. и др. Организация проведения профилактиче ского медицинского осмотра и диспансеризации определенных групп взрослого населения. Методические рекомендации. Издание 2-е. М.: ФГБУ “НМИЦ ТПМ” Минздрава России, 2020. 232 с. https://org.gnicpm.ru/wp-content/uploads/2020/07/organizacziya-provedeniya_4_tip.pdf.

427. Vanlaar WG, Mainegra Hing M, Robertson RD. An evaluation of Nova Scotia’s alcohol ignition interlock program. Accid Anal Prev. 2017;100:44-52. doi:10.1016/j.aap.2016.12.017.

428. Fell JC. Approaches for reducing alcohol-impaired driving: Evidence-based legislation, law enforcement strategies, sanctions, and alcohol-control policies. Forensic Sci Rev. 2019;31(2):161-84.

429. Neufeld M, Rehm J. Effectiveness of policy changes to reduce harm from unrecorded alcohol in Russia between 2005 and now. Int J Drug Policy. 2018;51:1-9. doi:10.1016/j.drugpo.2017.09.006.

430. Sherk A, Stockwell T, Chikritzhs T, et al. Alcohol Consumption and the Physical Availability of Take-Away Alcohol: Systematic Reviews and Meta-Analyses of the Days and Hours of Sale and Outlet Density. J Stud Alcohol Drugs. 2018;79(1):58-67.

431. Wettlaufer A, Cukier SN, Giesbrecht N. Comparing Alcohol Marketing and Alcohol Warning Message Policies Across Canada. Subst Use Misuse. 2017;52(10):1364-74. doi:10.1080/10826084.2017.1281308.

432. Burton R, Henn C, Lavoie D, et al. A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective. Lancet. 2017;389(10078):1558-80. doi:10.1016/S0140-6736(16)32420-5.

433. Sharma A, Sinha K, Vandenberg B. Pricing as a means of controlling alcohol consumption. Br Med Bull. 2017;123(1):149-58. doi:10.1093/bmb/ldx020.

434. Siegfried N, Parry C. Do alcohol control policies work? An umbrella review and quality assessment of systematic reviews of alcohol control interventions (2006-2017). PLoS One. 2019;14(4):e0214865. doi:10.1371/journal.pone.0214865.

435. O’Connor EA, Perdue LA, Senger CA, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(18):1910-28. doi:10.1001/jama.2018.12086.

436. Tan CH, Hungerford DW, Denny CH, McKnight-Eily LR. Screening for Alcohol Misuse: Practices Among U. S. Primary Care Providers, DocStyles 2016. Am J Prev Med. 2018;54(2):173-80. doi:10.1016/j.amepre.2017.11.008.

437. Higgins-Biddle JC, Babor TF. A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: Past issues and future directions. Am J Drug Alcohol Abuse. 2018;44(6):578-86. doi:10.1080/00952990.2018.1456545.

438. Vodopyanova NE. Psychodiagnostics of stress. St. Petersburg: St. Petersburg, 2009. 336 p. (In Russ.) Водопьянова Н. Е. Психодиагностика стресса. СПб.: Питер, 2009. 336 с.

439. Котова М. Б., Розанов В. Б., Иванова Е. И. Ассоциация самооценки здоровья с социальнопсихологической средой, образом жизни и маркерами риска сердечно-сосудистых заболеваний у мужчин среднего возраста, проживающих в г. Москве. Рациональная Фармакотерапия в Кардиологии. 2019;15(6):768-78.

440. Smulevich AB. Depression in general medicine. Guide for doctors. M.: Medical Information Agency. 2001. 782 p. (In Russ.) Смулевич А. Б. Депрессии в общей медицине. Руководство для врачей. М.: Медицинское информационное агентство. 2001. 782 с.

441. Погосова Н. В., Довженко Т. В., Бабин А. Г. и др. Русскоязычная версия опросников PHQ-2 И 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24.

442. Riedl D, Schüßler G. The Infuence of doctor–patient communication on health outcomes: a systematic review. Z Psychosom Med Psychother. 2017;63(2):131-50. doi:10.13109/zptm.2017.63.2.131.

443. Whalley B, Rees K, Davies P, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2011;(8):CD002902. doi:10.1002/14651858.CD002902.pub3. Update in: Cochrane Database Syst Rev. 2017;4:CD002902.

444. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22:1290-306.

445. Thompson DR, Ski CF. Psychosocial interventions in cardiovascular disease — what are they? Eur J Prev Cardiol. 2013;20(6):916-7. doi:10.1177/2047487313494031.

446. Rebar AL, Stanton R, Geard D, et al. A meta-meta-analysis of the effect of physical activity on depression and anxiety in nonclinical adult populations. Health Psychol Rev. 2015;9(3):366-78. doi:10.1080/17437199.2015.1022901.

447. Бильданова В. Р., Бисерова Г. К., Шагивалее Г. Р. Психология стресса и методы его профилактики: учебно-методическое пособие. Елабуга: Изд-во ЕИ КФУ. 2015. 142 c.

448. Bostock S, Crosswell AD, Prather AA, Steptoe A. Mindfulness onthe-go: Effects of a mindfulness meditation app on work stress and well-being. J Occup Health Psychol. 2019;24(1):127-38. doi:10.1037/ocp0000118.

449. Pizzi C, Rutjes AW, Costa GM, et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107:972-9.

450. Kim JM, Stewart R, Lee YS, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018;320:350-8.

451. He W, Zhou Y, Ma J, et al. Effect of antidepressants on death in patients with heart failure: a systematic review and metaanalysis. Heart Fail Rev. 2020;25:919-26.

452. Honkola J, Hookana E, Malinen S, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33:745-51.

453. Программы скрининга: краткое руководство. Повышение эффективности, максимальное увеличение пользы и минимизация вреда. Копенгаген: Европейское региональное бюро ВОЗ, 2020. https://apps.who.int/iris/bitstream/handle/10665/330828/9789289054812-rus.pdf.

454. Order of the Ministry of Health and Social Development of the Russian Federation No. 543n dated 15.05.2012 “On approval of the Regulations on the organization of primary health care for adults”. (In Russ.) Приказ Министерства здравоохранения и социального развития Российской Федерации от 15.05.2012 № 543н “Об утверждении Положения об организации оказания первичной медико-санитарной помощи взрослому населению”. http://www.consultant.ru/document/cons_doc_LAW_132071.

455. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-27. doi:10.1111/j.1360-0443.1991.tb01879.x.

456. Miller SD, Berg I. Working with the problem drinker: A solutionfocused approach. Arizona Counseling Journal. 1991;16(1):3-12.

457. Приказ Минздрава России от 26 февраля 2021г. № 140н “Об утверждении Порядка оказания медицинской помощи взрослому населению по прекращению потребления табака или никотинсодержащей продукции, лечению табачной (никотиновой) зависимости, последствий потребления, табака или никотинсодержащей продукции. http://www.consultant.ru/document/cons_doc_LAW_379416.

458. West R, McNeill A, Britton J, et al. Should smokers be offered assistance with stopping? Addiction. 2010;105(11):1867-9. doi:10.1111/j.1360-0443.2010.03111.x.

459. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292. doi:10.1002/14651858.CD001292.pub2. Update in: Cochrane Database Syst Rev. 2017;3:CD001292.

460. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;2013(5):CD000165. doi:10.1002/14651858.CD000165.pub4.

461. Wang MP, Suen YN, Li WH, et al. Intervention With Brief Cessation Advice Plus Active Referral for Proactively Recruited Community Smokers:, A Pragmatic Cluster Randomized Clinical Trial JAMA Intern Med. 2017;177(12):1790-7. doi:10.1001/jamainternmed.2017.5793.

462. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;3:CD008286. doi:10.1002/14651858.CD008286.pub3.

463. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2015;(10):CD009670. doi:10.1002/14651858.CD009670.pub3.

464. Seabury SA, Dougherty JS, Sullivan J. Medication adherence as a measure of the quality of care provided by physicians. Am J Manag Care. 2019;25:78-83.

465. Лукина Ю. В., Кутишенко Н. П., Марцевич С. Ю. и др. Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций. Профилактическая медицина. 2020;23(3):2042-60. doi:10.17116/profmed20202303242.

466. Reach G. Temporality in chronic diseases and adherence to long-term therapies: From philosophy to science and back. Diabetes Metab. 2019;45(5):419-28. doi:10.1016/j.diabet.2018.11.002.

467. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882-887e881.

468. Bosworth H, Granger B, Mendys P, et al. Medication adherence: A call for action. Am Heart J. 2011;162:412-24.

469. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-84. doi:10.2337/dc11-1277.

470. Rasmussen J, Chong A, Alter D. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.

471. Ho P, Bryson C, Rumsfeld J. Medication adherence: Its importance in cardiovascular outcomes. Circulation. 2009;11:3028-35.

472. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.

473. Brown MT, Bussell J, Dutta S, et al. Medication Adherence: Truth and Consequences. Am J Med Sci. 2016;351:387-99.

474. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. doi:10.1056/NEJMra050100.

475. Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. Questionnaires and scales for assessing adherence to treatment — advantages and disadvantages of the diagnostic method in scientific research and real clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):2562. (In Russ.)

476. Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. Development and validation of new questionnaires in medicine on the example of the scale of adherence to drug therapy. Rational Pharmacotherapy in Cardiology. 2021;17(4):576-83. (In Russ.)

477. Hennein R, Hwang SJ, Au R, et al. Barriers to medication adherence and links to cardiovascular disease risk factor control: the Framingham Heart Study. Intern Med J. 2018;48:414-21.

478. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail: addressing psychological risk factors of nonadherence. Curr Opin Psychiatry. 2017;30:326-33.

479. Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract. 2019;27:223-31.

480. Schneider APH, Gaedke MÂ, Garcez A, et al. Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease: A systematic review and metaanalysis of observational studies. Int J Clin Pract. 2018;72(1). doi:10.1111/ijcp.13044.

481. Nieuwlaat R., Wilczynski N., Navarro T, et al. Intervention for enhancing medication adherence (review). Cochrane Database Syst Rev. 2014;(11):CD000011. doi:10.1002/14651858.CD000011.pub4.

482. Keenan J. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol. 2017;24(3_suppl):29-35. doi:10.1177/2047487317708145.

483. Albarqouni L, Doust J, Glasziou P. Patient preferences for cardiovascular preventive medication: a systematic review. Heart. 2017;103:1578-86.

484. Hoorn CJGM, Crijns HJGM, Dierick-van Daele, et al. LRC. Review on Factors Influencing Physician Guideline Adherence in Cardiology. Cardiology in Review. 2019;27(2):80-6. doi:10.1097/CRD.0000000000000207.

485. Komajda M, Schöpe J, Wagenpfeil S, et al.; QUALIFY Investigators. Physicians’ guideline adherence is associated with longterm heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2019 Jul;21(7):921-929. doi: 10.1002/ejhf.1459.

486. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.

487. Hense HW, Schulte H, Lowel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany — results from MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;3:1-9

488. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267-70.

489. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

490. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021:39:1293-302.

491. Stergiou GS, Alpert B, Mieke S, et al. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ ESH/ISO) Collaboration Statement. J Hypertens. 2018;36:472-8.

492. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379:905-14.

493. Fagard RH, De Cort P. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly. Hypertension. 2010;56:56–61.

494. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92.

495. Kallioinen N, Hill A, Horswill MS, et al. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017;35:421-41.

496. O’Brien E, Parati G, Stergiou G, et al. ESH position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-68.

497. Salles GF, Reboldi G, Fagard RH, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693-700.

498. McManus RJ, Mant J, Bray EP, et al. Telemonitoring and selfmanagement in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376:163-72.

499. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

500. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455-67; discussion 467-458.

501. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension. 2010;55:195-200.

502. Смирнова М. И., Горбунов В. М., Кошеляевская Я. Н. и др. Характеристики больных с воспроизводимой скрытой артериальной гипертонией и подход к её диагностике. Рациональная фармакотерапия в кардиологии. 2019;15(6):789-94.

503. Pickering TG. Ambulatory Monitoring and Blood Pressure Variability. London: Science Press, 1991.

504. Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-9.

505. Mancia G, Bombelli M, Cuspidi C, et al. Cardiovascular risk associated with white-coat hypertension: pro side of the argument. Hypertension. 2017;70:668-75.

506. Mancia G, Fagard R, Narkiewicz, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. doi:10.1093/eurheartj/eht151.

507. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509-20.

508. Горбунов В. М., Смирнова М. И. Современные проблемы оценки эффективности антигипертензивной терапии: скрытая неэффективность лечения и “гипертония белого халата”. Рациональная фармакотерапия в кардиологии. 2009;3:76-82.

509. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902.

510. Parati G., Omboni S., Rizzoni D, et al. Smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685-91.

511. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EASGuidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.

512. Кухарчук В. В., Ежов М. В., Сергиенко И. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VII пересмотр. Атеросклероз и дислипидемии. 2020;1:7-40.

513. Amarenco P, Kim JS, Labreuche J, et al. Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382:9.

514. Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients with Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5:540-8.

515. Penson P, Martin SS, Henney NC, Banach M. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America. Eur Heart J. 2020;41(Suppl 2):2932.

516. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302-9.

517. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation. 2019;140:542-52.

518. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-53.

519. Dahlen GM. Incidence of Lp(a) lipoprotein among populations. In: Scanu AM (ed.). Lipoprotein(a): 25 Years in Progress. Academic Press Inc.; 1990:151-73.

520. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450-8. doi:10.1161/CIRCULATIONAHA.106.637793.

521. Wulff AB, Pedersen KM, Jensen GB, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2021:ehab705. doi:10.1093/eurheartj/ehab705. Epub ahead of print.

522. Nordestgraard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points — a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory medicine. Eur Heart J. 2016;37(25):1944-58. doi:10.1093/eurheartj/ehw152.

523. Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345-61.

524. Cartier LJ, Collins C, Lagace M, Douville P. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem. 2018;52:61-6.

525. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. 2012;380(9841):572-80. doi:10.1016/S0140-6736(12)60312-2.

526. Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015;36:2635-42. doi:10.1093/eurheartj/ehv236.

527. Madsen CM, Varbo A, Nordestgaard BG. Extreme High HighDensity Lipoprotein Cholesterol is Paradoxically Associated with High Mortality in Men and Women: two Prospective Cohort Studies. Eur Heart J. 2017;38:2478-86.

528. Метельская В. А. Функциональная многогранность липопротеинов высокой плотности: поиск золотой середины. Атеросклероз. 2021;17(2):61-71. doi:10.52727/2078-256X-2021-17-2-61-71.

529. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322:1381-91.

530. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387-97.

531. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713-22.

532. Ridker PM, Rose LM, Kastelein JJP, et al. Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018;12:958-65.

533. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J. 2016;37:1079-81.

534. Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr. 2016;104:1209-17.

535. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.

536. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61.

537. Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-107.

538. Cho L, Rocco M, Colquhoun D, et al. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovasc Drugs Ther. 2016;30:297-304.

539. Ray KK, Wright RS, Kallend D, et al. ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382:1507-19.

540. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634-9.

541. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020;396: 1644-652.

542. Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637-43.

543. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303-9.

544. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.

545. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337;a1840.

546. Bonaca MP, Bhatt DL, Cohen M, et al., for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015;372:1791-800. doi:10.1056/NEJMoa1500857.

547. Eikelboom JW, Connolly SJ, Bosch J, et al., for the COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. doi:10.1056/NEJMoa1709118.

548. Bhatt DL, Steg PG, Mehta SR, et al., on behalf of the THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169-80. doi:10.1016/S0140-6736(19)31887-2.

549. Hiatt WR, Bonaca MP, Patel MR, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020;142:2219-30. doi:10.1161/CIRCULATIONAHA.120.050465.

550. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.

551. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361:1045-57.

552. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-20.

553. McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379:1509-18.

554. Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252-63.

555. Токарева З. Н., Мамедов М. Н., Деев А. Д. и др. Распространенность и особенности проявлений метаболического синдрома во взрослой городской популяции. Кардиоваскулярная терапия и профилактика. 2010;9(1):10-4.

556. Pani LN, Korenda L, Meigs JB, et al. Effect of aging onA1Clevels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008;31:1991-6.

557. Мамедов М. Н., Корнеева М. Н., Поддубская Е. А., Дудинская Е. Н. Ранние нарушения углеводного обмена: диагностика и лечение в кардиологической практике. Москва. ГНИЦ ПМ. 2017. 108 с. doi:10.17116/profmed2017posob01.

558. Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020;41(45):4317.

559. Pippitt K, Li M, Gurgle HE. Diabetes Mellitus: Screening and Diagnosis. Am Fam Physician. 2016;93(2):103-9.

560. WHO. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. https://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf.

561. Mainous AG 3rd, Tanner RJ, Baker R. Prediabetes Diagnosis and Treatment in Primary Care. J Am Board Fam Med. 2016;29(2):283-5.

562. Tuomilehto J, Lindström J, Hellmich M, et al. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score. Diabetes Res Clin Pract. 2010;87(2):267-74. doi:10.1016/j.diabres.2009.11.011.

563. Ratner R, Goldberg R, Haffner S, et al; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28(4):888-94. doi:10.2337/diacare.28.4.888.

564. American Diabetes Association. Lifestyle management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S38-S50. doi:10.2337/dc18-S004.

565. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015;163:437-51.

566. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39:2065-79.

567. Burton R, Sheron N. No level of alcohol consumption improves health. Lancet. 2018. 392(10152):987-8. doi:10.1016/S0140-6736(18)31571-X.

568. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care 2019;42:416-26

569. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7:221-30.

570. U. K. Prospective Diabetes Study Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet. 1998;352(9131):837-53. Erratum in: Lancet 1999;354(9178):602.

571. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. doi:10.1056/NEJMoa0808431. Erratum in: N Engl J Med. 2009;361(10):1028. Erratum in: N Engl J Med. 2009;361(10):1024-5.

572. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. doi:10.1056/NEJMoa0802743.

573. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-58. doi:10.1111/1755-5922.12075.

574. Savarese G, Perrone-Filardi P, D’Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Int J Cardiol. 2015;181:239-44. doi:10.1016/j.ijcard.2014.12.017.

575. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96(1133):156-61. doi:10.1136/postgradmedj-2019-137186.

576. Johansen M, Argyropoulos C. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now. Clin Cardiol. 2020;43(12):1376-87. doi:10.1002/clc.23508.

577. Jhund PS, Ponikowski P, Docherty KF, et al. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021;143:1962-72. doi:10.1161/CIRCULATIONAHA.121.053659.

578. Чучалин А. Г., Халтаев Н., Антонов Н. С. и др. Хронические респираторные заболевания и факторы риска в 12 регионах Российской Федерации. Международный журнал хронической обструктивной болезни легких. 2014;9:963-74. doi:10.2147/COPD.S67283.

579. Global strategy for prevention, diagnosis and management of COPD (2022 report). https://goldcopd.org/2022-gold-reports.

580. Levy ML. National Review of Asthma Deaths (NRAD). Br J Gen Pract. 2014;64(628):564. doi:10.3399/bjgp14X682237.

581. Концевая А. В., Муканеева Д. К., Баланова Ю. А. и др. Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году. Пульмонология. 2019;29(2):159-66.

582. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385(9971):899-909. doi: 10.1016/S0140-6736(14)60446-3.

583. Гамбарян М. Г., Калинина А. М., Шальнова С. А. и др. Эпидемиологические особенности хронических респираторных заболеваний в разных климатогеографических регионах России. Пульмонология. 2014;3:55-61.

584. Stoller JK, Aboussouan LS. A review of a1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3):246-59.

585. Li YF, Langholz B, Salam MT, Gilliland FD. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest. 2005;127:1232-41.

586. Doruk S, Ozyurt H, Inonu H, et al. Oxidative status in the lungs associated with tobacco smoke exposure. Clin Chem Lab Med. 2011;49:2007-12.

587. Eisner MD, Balmes J, Katz PP, et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health. 2005;4(1):7. doi:10.1186/1476-069X-4-7.

588. Хроническая обструктивная болезнь легких. Клинические рекомендации 2021. Российское респираторное общество. http://disuria.ru/_ld/10/1081_kr21J44MZ.pdf.

589. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2021 Report https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.

590. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675-9. doi:10.1164/rccm.2112096.

591. Shea KM, Edelsberg J, Weycker D, et al. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi:10.1093/ofid/ofu024.

592. Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. MMWR. 2020;69(RR-3):77-83.

593. Segrelles-Calvo G, López-Padilla D. Telemedicine Programs in Respiratory Diseases. Mobile Health Technologies — Theories and Applications. Wilfred Bonney, Intech. 2016 doi:10.5772/64705.

594. Lu JW, Wang Y, Sun Y, et al. Effectiveness of Telemonitoring for Reducing Exacerbation Occurrence in COPD Patients With Past Exacerbation History: A Systematic Review and MetaAnalysis. Front Med (Lausanne). 2021;8:720019. doi:10.3389/fmed.2021.720019.

595. Авдеев С. Н., Айсанов З.Р., Белевский А.С. и др. Концепция контроля хронической обструктивной болезни легких как инструмент принятия решения и оптимизации базисной терапии в реальной клинической практике. Терапевтический архив. 2020;92(1):89-95.

596. Drapkina OM, Martynov AI, Avdeev SN, et al. Dispensary observation of patients with respiratory diseases by a district therapist. resolution of experts of the Russian Scientific Medical Society of Therapists and the Russian Society for the Prevention of Non-communicable Diseases. Preventive medicine. 2021;24(1):7-10. (In Russ.) Драпкина О. М., Мартынов А. И., Авдеев С. Н. и др. Диспансерное наблюдение пациентов с болезнями органов дыхания участковым терапевтом. резолюция экспертов российского научного медицинского общества терапевтов и российского общества профилактики неинфекционных заболеваний. Профилактическая медицина. 2021;24(1):7-10.

597. Bronchial asthma. Clinical guidelines 2021. The Russian Respiratory Society, the Russian Association of Allergologists and Clinical Immunologists, the Union of Pediatricians of Russia. (In Russ.) Бронхиальная астма. Клинические рекомендации 2021. Российское респираторное общество, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России. http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf.

598. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: www.ginasthma.org.

599. Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis. J Allergic Clin Immunol. 2011;127:724-33.e1-30.

600. Stensballe LG, Simonsen J, Jensen SM, et al. Use antibiotics during pregnancy increases the risk of asthma in early childhood. J Pediatr. 2013;162:832-8.e3.

601. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591-604. doi:10.1111/j.1398-9995.2007.01394.x.

602. Mukherjee M, Stoddart A, Gupta RP, et al. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med. 2016;14:113. doi:10.1186/s12916-016-0657-8.

603. Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. [Erratum appears Eur Respir J. 2012;39(6):1553]. Eur Respir J. 2012;39:529-45.

604. Hansen ESH, Pitzner-Fabricius A, Toennesen LL, et al. Effect of aerobic exercise training on asthma in adults: a systematic review and meta-analysis. Eur Respir J. 2020;56(1):2000146.

605. Pneumococcal vaccines WHO position paper — 2012. Wkly Epidemiol Rec. 2012;87(14):129-44.

606. Чучалин А. Г., Биличенко Т. Н., Осипова Г. Л. и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению. Пульмонология. 2015;25(2), Приложение:4-19.

607. Приказ Минздрава РФ от 31.07.2020 г № 788н “Об утверждении порядка медицинской реабилитации взрослых”. https://normativ.kontur.ru/document?moduleId=1&documentId=372352.

608. Chongmelaxme B, Lee S, Dhippayom T, et al. The Effects of Telemedicine on Asthma Control and Patients’ Quality of Life in Adults: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1):199-216.e11. doi:10.1016/j.jaip.2018.07.015.

609. Lim A, Stewart K, Konig K, George J. Systematic review of the safety regular preventive ashma medication during pregnancy. Ann Pharmacother. 2021;45:931-45.

610. Kong DL, Qin Z, Shen H, et al. Association of Obstructive Sleep Apnea with Asthma: A Meta-Analysis. Sci Rep. 2017;7(1):4088. doi:10.1038/s41598-017-04446-6.

611. Rock CL, Thomson C, Gansler T, et al. American Cancer Society Guideline for Diet and Physical Activity for Cancer Prevention CA Cancer J Clin. 2020;70:245-71.

612. Djuric Z. Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state. Transl Res. 2017;179:155-67.

613. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54.

614. Leitzmann M, Powers H, Anderson AS, et al. European Code against Cancer 4th Edition: Physical activity and cancer. Cancer Epidemiol. 2015;39(1):S46-55. doi:10.1016/j.canep.2015.03.009.

615. International Agency for Research on Cancer (IARC) Monographs Working Group. Consumption of Red Meat and Processed Meat. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 114. WHO/IARC; 2015.

616. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. 2013;359-64. doi:10.14694/EdBook_AM.2013.33.359.

617. Das A, Krishnamurthy A, Ramshankar V, et al. The increasing challenge of never smokers with adenocarcinoma lung: Need to look beyond tobacco exposure. Indian J Cancer. 2017;54(1):172-77. doi:10.4103/ijc.IJC_33_17.

618. Bhopal A, Peake MD, Gilligan D, Cosford P. Lung cancer in never-smokers: a hidden disease. JRSM. 2019;112(4):269-71. doi:10.1177/0141076819843654.

619. García-Pérez J, Fernández de Larrea-Baz N, Lope V, et al. Residential proximity to industrial pollution sources and colorectal cancer risk: A multicase-control study (MCC-Spain). Environ Int. 2020;144:106055. doi:10.1016/j.envint.2020.106055.

620. Hamer J, Warner E. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. CMAJ. 2017;189:E268-74. doi:10.1503/cmaj.160464.

621. Lahart IM, Metsios GS, Nevill AM, et al. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta Oncol. 2015;54:635-54.

622. Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelinesand survival after breast cancer: findings from the After Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012;131:637-43.

623. Playdon MC, Bracken MB, Sanft TB, et al. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst. 2015;107:djv275.

624. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767-76.

625. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and metaanalysis of observational studies. Cancer Med. 2015;4:1933-47.

626. Shaikh H, Bradhurst P, Ma LX, et al. Body weight management in overweight and obese breast cancer survivors. Cochrane Database of Systematic Reviews. 2020;12. Art. No.: CD012110. doi:10.1002/14651858.CD012110.pub2.

627. van Zutphen M, van Duijnhoven FJB, Wesselink E, et al. Identification of Lifestyle Behaviors Associated with Recurrence and Survival in Colorectal Cancer Patients Using Random Survival Forests. Cancers. 2021;13:2442. doi:10.3390/cancers13102442.

628. van Zutphen M, Boshuizen HC, Kenkhuis MF, et al. Lifestyle after colorectal cancer diagnosis in relation to recurrence and allcause mortality. Am J Clin Nutr 2021;113:1447-57.

629. van Zutphen M, Kampman E, Giovannucci EL, van Duijnhoven FJB. Lifestyle after Colorectal Cancer Diagnosis in Relation to Survival and Recurrence: A Review of the Literature. Curr Colorectal Cancer Rep. 2017;13(5):370-401. doi:10.1007/s11888-017-0386-1.

630. Jung AY, Behrens S, Schmidt M, et al. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors. Breast Cancer Res. 2019;21(1):117. doi:10.1186/s13058-019-1206-0.

631. Van Blarigan EL, Fuchs CS, Niedzwiecki D, et al. Association of survival with adherence to the American cancer society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: the CALGB 89803/Alliance trial. JAMA Oncol. 2018;4(6):783-90. doi:10.1001/jamaoncol.2018.0126.

632. Zaridze DG, Mukeria AF. The influence of smoking on the prognosis of the disease in cancer patients. Questions of oncology. 2019;65(3):321-9. (In Russ.) Заридзе Д. Г., Мукерия А. Ф. Влияние курения на прогноз заболевания у онкологических больных. Вопросы онкологии. 2019;65(3):321-9.

633. Declaration from IASLC: tobacco cessation after cancer diagnosis. Accessed Dec. 09.2019. https://www.iaslc.org/AboutIASLC/News-Detail/declaration-from-iaslc-tobacco-cessationafter-cancer-diagnosis.

634. WHO. Cancer. Newsletter. February 2017. (In Russ.) ВОЗ. Рак. Информационный бюллетень. Февраль 2017 г. http://www.who.int/mediacentre/factsheets/fs297/ru/

635. Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М, 2017;(250):4-5.

636. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015; 12(11):620.

637. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102-11.

638. Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90. doi:10.1016/j.annonc.2019.10.023.

639. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801. doi:10.1093/eurheartj/ehw211.

640. Гарднер Р. С., МакДонаг Т. А., Уолкер Н. Л. Сердечная недостаточность. Под ред. С. Н. Терещенко; пер. с англ. Д. А. Струтынский. М.: МЕДпресс-информ, 2014. 360 с. ISBN: 978-5-00030-147-0.

641. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33(1):2-14. doi:10.1053/j.seminoncol.2005.11.001.

642. Сердечно-сосудистые осложнения противоопухолевой терапии: диагностика, профилактика, лечение. Под ред. И. Е. Чазовой, М. В. Вицени, Ф. Т. Агеева. М.: ГРАНАТ, 2019. 160 с.

643. Васюк Ю. А., Ющук Е. Н., Несветов В. В. Кардиоонкология: новый вызов нашего времени. Сердечнососудистые осложнения противоопухолевого лечения. Монография, Москва, ООО “КЛИНМЕД КОНСАЛТИНГ”, 2019. 100 с. ISBN: 978-5-904148-04-1.

644. Plana J. C., Galderisi M., Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-93. doi:10.1093/ehjci/jeu192.

645. Семенова А. И. Кардио и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение) Практическая онкология. 2009;10(3):168.

646. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014;5(4):154-66. doi:10.1177/2042098614529603.

647. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106(1):35-46. doi:10.1161/CIRCRESAHA.109.205906.

648. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumabinduced cardiac dysfunction: A ‘dual-hit’. Exp Clin Cardiol. 2011;16(3):70-4.

649. Каприн А. Д., Мацкеплишвили С. Т., Потиевская В. И. и др. Сердечно-сосудистые заболевания у онкологических пациентов. Онкология. Журнал института им. П. А. Герцена. 2019;8(2):139-47. doi:10.17116/onkolog20198021139.

650. Гендлин Г. Е., Емелина Е. И., Никитин И. Г., Васюк Ю. А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017;(3):145-54. doi:10.15829/1560-4071-2017-3-145-154.

651. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Научное общество нефрологов. http://www.nephro.ru/content/files/standards/ckdru.pdf.

652. Смирнов А. В., Добронравов В. А., Каюков И. Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология. 2006;10(1):7-13.

653. Tsai WC, Wu HY, Peng YS, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. doi:10.1097/MD.0000000000003013.

654. Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. doi:10.1371/journal.pone.0192895.

655. Хроническая болезнь почек (ХБП) Ассоциация нефрологов 2021. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf.

656. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease: a randomized placebo-controlled trial. SHARP (Study of Heart and Renal Protection) Investigators. Lancet 2011; 377: 2181-2192.

657. Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. FOURIER Steering Committee and Investigators. J Am Coll Cardiol 2019; 73: 2961-2970.

658. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. DAPA-CKD Trial Committees and Investigators. N Engl J Med 2020; 383: 1436-1446.

659. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9-17. doi:10.5665/sleep.3298.

660. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health. 2015;1(1):40-3. doi:10.1016/j.sleh.2014.12.010.

661. Watson NF, Badr MS, Belenky G, et al. Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-4. doi:10.5665/sleep.4716.

662. Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.

663. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr. Clin. North Am. 1987;10:541-53.

664. Lichstein KL, Taylor DJ, McCrae CS, et al. Insomnia: epidemiology and risk factors. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016. pp. 761-8. doi:10.1016/B978-1-4160-6645-3.00076-1.

665. Бочкарев М. В., Коростовцева Л. С., Фильченко И. А. и др. Социальнодемографические аспекты инсомнии в российской популяции по данным исследования ЭССЕ-РФ. Журнал неврологии и психиатрии им. С. С. Корсакова. Спецвыпуски. 2018;118(4-2):26-34. doi:10.17116/jnevro20181184226.

666. Пчелина П. В., Полуэктов М. Г. Эволюция инсомнии: переход из кратковременной в хроническую. Медицинский совет. 2020;(19):70-7. doi:10.21518/2079-701X-2020-19-70-77.

667. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841-58. doi:10.1016/j.jacc.2016.11.069.

668. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. doi:10.1001/jama.284.23.3015.

669. Boivin DB, Tremblay GM, James FO. Working on atypical schedules. Sleep Med 2007;8(6):578-89. doi:10.1016/j.sleep.2007.03.015.

670. Dodson ER, Zee PC. Therapeutics for Circadian Rhythm Sleep Disorders. Sleep Med Clin. 2010;5(4):701-15. doi:10.1016/j.jsmc.2010.08.001.

671. Principles and Practice of Sleep Medicine (Sixth Edition). Editor(s): Kryger M, Roth T, Dement WC. Elsevier, 2017. ISBN: 9780323242882. doi:10.1016/B978-0-323-24288-2.00180-X.

672. Kanis A, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. J Osteoporos Int. 2019;30:3-44.

673. Меньшикова Л. В., Храмцова Н. А., Ершова О. Б. и др. Исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия. Научно-практическая ревматология. 2002;(4):11-4.

674. Opeyemi O. Babatunde. Primary Prevention of Osteoporosis: Time to Redefine the Wheel? J Osteopor Phys Act. 2013;2(1):e107.

675. Никитинская О. А., Торопцова Н. В. Оценка 10-летней вероятности остеопоротических переломов с помощью российской модели FRAX. Медицинский совет. 2017;(1S):103-7.

676. Skripnikova IA, Myagkova MA, Shalnova SA, et al. Estimation of bone fracture risk using FRAX® model in some regions of Russian Federation. International Journal of Clinical Rheumatology. 2018;13(2):63-70.

677. Риггз Л. Б., Мелтон Л. Д. Остеопороз. Этиология, диагностика, лечение. Перевод с англ. Под редакцией Е. А. Лепарского. М., “Невский диалект”, 2000:363-81.

678. Ткачева О.Н, Котовская Ю.В., Розанов А.В. и др. Комплекс мер, направленный на профилактику падений и переломов у лиц пожилого и старческого возраста. Методические рекомендации. https://legalacts.ru/doc/metodicheskie-rekomendatsii-kompleks-mernapravlennyi-na-profilaktiku-padenii-i.

679. Hawley S, Javaid MK, Prieto-Alhambra D, et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing. 2016;45(2):236-42.

680. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-82.

681. Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011;22 Suppl 3:457-60.

682. Osteoporosis. Clinical Guidelines, 2021. (In Russ.) Остеопороз. Клинические рекомендации, 2021. https://cr.minzdrav.gov.ru/recomend/87_4.

683. Nutritional aspects of osteoporosis. Ed. Burckhardt P, DawsonHughes B, Heaney RP. Academic Press. 2001; pp. 263-268, 273-281,295-302.

684. Chemical composition of food products used in the Russian Federation. Information and analytical system. (In Russ.) Химический состав пищевых продуктов, используемых в Российской Федерации. Информационно-аналитическая система. http://web.ion.ru/food/FD_tree_grid.aspx.

685. Профилактика, диагностика и лечение дефицита витамина D и кальция среди взрослого населения и у пациентов с остеопорозом. Рекомендации Российской ассоциации по остеопорозу. Под ред. О. М. Лесняк. М.: ГЭОТАРМедиа, 2016. 94 с.

686. Батурин А. К. Состояние питания и пути его оптимизации. Федеральные и региональные аспекты. Материалы Всероссийской научно-практической конференции “Здоровое питание — здоровая нация”, 2009;2:89-90.

687. Schramm S, Lahner H, Jöckel KH, et al. Nixdorf Recall Study Group. Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts — A note of caution. Endocrine. 2017;56:658-66.

688. Каронова Т. Л., Гринева Е. Н., Никитина И. Л. и др. Распространенность дефицита витамина D в Северо-западном регионе РФ среди жителей г. Санкт-Петербурга и г. Петрозаводска. остеопороз и остеопении. 2013.3:3-7.

689. Gomez de Tejada Romero MJ, Sosa Henriquez M, Del Pino Montes J, et al. Position document on the requirements and optimum levels of vitamin D. Rev Osteoporos Metab Miner. 2011.3(1):53-64.

690. Weaver CM, Alexander DD, Boushey СJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. J Оsteoporos Int. 2016;27(1):367-76.

691. Bolland MJ, Grey A, Gamble GD, et al. Vitamin D supplementation and falls: atrial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014;2(7):573-80.

692. Richy F, Dukas L, Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue Int 2008;82(2):102-7.

693. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-59. doi:10.1016/j.jamda.2013.05.021.

694. Спиричев В. Б. Витамины и обогащенные ими продукты в питании и поддержании здоровья современного человека. Вопросы диетологии. 2012;2(3):31-4.

695. Baber R, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. doi:10.3109/13697137.2015.1129166.

696. Евстигнеева Л. П. Немедикаментозные методы лечения остеопороза. Альманах клинической медицины. 2014;73(32):73-9.

697. Dishman R, Heath GW, Schmidt MD, Lee I-M. Physical activity epidemiology. Human kinetics. Third edition. 2018;Part 4;672p.

698. De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330-8. doi:10.1007/s00198-005-1863-y.

699. Скрипникова И. А., Оганов Р. Г. Остеопороз и сердечно-сосудистые заболевания, обусловленные атеросклерозом, у женщин постменопаузального периода: общность поведенческих и социальных факторов риска. Остеопороз и остеопатии. 2009;12(2):5-9.

700. Premaor M. O., Pilbrow L., Tonkin C. et al. Obesity and fractures in postmenopausal women. J. Bone Miner. Res 2010; 25(2): 292-297.

701. Ганиева И. И., Карабиненко А. А., Еремина C. С. и др. Влияние курения на костную ткань. Состояние проблемы. Лечебное дело. 2013;(1):4-8.

702. ISCD Official Positions — Adult 2019. http://www.iscd.org/official-positions/2019 (последнее посещение: 15.01.21

703. Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010;6:360-2.

704. Johansson H, Oden A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014;94:560-7.

705. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007.

706. Johnson SL, Petkov VI, Williams MI, et al. Improving osteoporosis management in patients with fractures. Osteoporos Int. 2005;16(9):1079-85.

707. Программа профилактики, раннего выявления, диагностики и лечения когнитивных расстройств у лиц пожилого и старческого возраста. Методические рекомендации. Под ред. Ткачевой О. Н. М.: Издательство “Прометей”, 2019. 72 с.

708. Левин О. С. Диагностика и лечение когнитивных нарушений и деменции в клинической практике. М.: МЕДпресс-информ, 2021. 448 с.

709. Alnefeesi Ya, Siegel A, Lui LMW, et al. Impact of SARS-CoV-2 infection on cognitive function: a systematic review. Front Psychiatry. 2021;11:621773. doi:10.3389/fpsyt.2020.621773.

710. Wandell PE, de Waard AM, Holzmann MJ, et al. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: A systematic review. Fam Pract. 2018;35(4):383-98. doi:10.1093/fampra/cmx137.

711. An J, Li H, Tang Z, et al. Cognitive Impairment and Risk of All‐ Cause and Cardiovascular Disease Mortality Over 20‐Year Follow‐up: Results From the BLSA. Journal of the American Heart Association. 2018;7(15):e008252. doi:10.1161/JAHA.117.008252.

712. Su Y, Dong J, Sun J, et al. Cognitive function assessed by Mini-mental state examination and risk of all-cause mortality: a community-based prospective cohort study. BMC Geriatr. 2021;21(1):524. doi:10.1186/s12877-021-02471-9.

713. Luksiene D, Sapranaviciute-Zabazlajeva L, Tamosiunas A, et al. Lowered cognitive function and the risk of the first events of cardiovascular diseases: findings from a cohort study in Lithuania. BMC Public Health. 2021;21(1):792. doi:10.1186/s12889-021-10843-4.

714. Rakesh G, Szabo ST, Alexopoulos GS. Strategies for dementia prevention: latest evidence and implications. Ther Adv Chronic Dis. 2017;8(8-9):121-36. doi:10.1177/2040622317712442.

715. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202.

716. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505. doi:10.1111/head.1328.

717. Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373-81. doi:10.1177/0333102412438977.

718. Филатова Е. Г., Осипова В. В., Табеева Г. Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi:10.14412/2074-2711-2020-4-4.

719. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498. doi:10.1136/bmjopen-2017-020498.

720. Adelborg K, Szepligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.

721. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep 2014;16:524.

722. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case control study. The WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 1999;318:13-8.

723. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.

724. Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1-489.e7. doi:10.1016/j.ajog.2016.12.019.

725. Ornello R, Canonico M, Merki-Feld GS, et al. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and sug gestions for future research. Expert Rev Neurother. 2020;20:313-7.

726. Sacco S, Merki-Feld GS, KL AE, et al. European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18:108.

727. Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66. doi:10.15829/1728-8800-2019-1-5-66.

728. Multimorbidity: clinical assessment and management. National Guideline Centre. London (UK): National Institute for Health and Care Excellence (NICE); 2016. 23 p. (NICE guideline; no. 56).

729. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.

730. Оганов Р. Г., Денисов И. Н., Симаненков В. И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56. doi:10.15829/1728-8800-2017-6-5-56.

731. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):E1-E25. doi:10.1111/j.1532-5415.2012.04188.x.

732. Parekh A, Goodman R, Gordon C, Koh H. Managing multiple chronic conditions (MCC): a strategic framework for improving health outcomes and quality of life. Public Health Rep. 2011;126(4):460-71. doi:10.1177/003335491112600403.

733. Leppin L, Montori V, Gionfriddo M. Minimally Disruptive Medicine Care Model for patients with multiple chronic conditions. Healthcare (Basel). 2015;3:50-63. doi:10.3390/healthcare3010050.

734. Muth C, van den Akker M, Blom J, et al. Ariadne principles to handle multimorbidity in primary care consultations. BMC Med. 2014;12:223. doi:10.1186/s12916-014-0223-1.

735. Violan C, Bejarano-Rivera N, Foguet-boreu Q, et al. The burden of cardiovascular morbidity in a European Mediterranean population with multimorbidity; a cross-sectional study. BMC Family Practice. 2016;17:150. doi:10.1186/s12875-016-0546-4.

736. Smith S, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.

737. Драпкина О. М., Самородская И. В., Ларина В. Н., Лукьянов М. М. Вопросы организации помощи пациентам с мультиморбидной патологией (аналитический обзор международных и российских рекомендаций). Профилактическая медицина, 2019,2:107-14. doi:10.17116/profmed201922021107.

738. Андреенко Е. Ю., Лукьянов М. М., Якушин С. С. и др. Ранняя кардиоваскулярная мультиморбидность в амбулаторной и госпитальной практике: возрастные характеристики и медикаментозное лечение (данные регистров РЕКВАЗА и РЕКВАЗА-КЛИНИКА). Кардиоваскулярная терапия и профилактика. 2020;19(5):2672. doi:10.15829/1728-8800-2020-2672.

739. Cohen-Stavi CJ, Giveon S, Key C, et al. Guideline deviation and its association with specific chronic diseases among patients with multimorbidity: a cross-sectional cohort study in a care management setting. BMJ Open. 2021;11:e040961. doi:10.1136/bmjopen-2020-040961.

740. Forslund T, Carisson AC, Ljunggren G, et al. Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Family Practice. 2021;38(2):132-40. doi:10.1093/fampra/cmaa056.

741. Бойцов С. А., Лукьянов М. М., Якушин С. С. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50. doi:10.15829/1728-8800-2014-6-3-8.

742. Марцевич С. Ю., Кутишенко Н. П., Лукина Ю. В. и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная терапия и профилактика. 2021;20(2):61-6. doi:10.15829/1728-8800-2021-2786.

743. Du Vaure CB, Ravaud P, Baron G, et al. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open. 2016;6:e010119. doi:10.1136/bmjopen-2015-010119.

744. Arnett DA, Goodman RA, Halperin JL, et al. AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions. Circulation. 2014;130:1662-7. doi:10.1161/CIR.0000000000000128.

745. Forouzanfar MM, Afskin A, Alexander LT, et al. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990- 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-724.

746. Charlson ME, Pompei P, MacKenzie A, MacKenzie RC. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-83.

747. Wilhelm M, Abreu A, Adami PE, et al. EAPC Core Curriculum for Preventive Cardiology. Eur J Prev Cardiol. 2022;29(1):251-74. doi:10.1093/eurjpc/zwab017. Erratum in: Eur J Prev Cardiol. 2021;28(15):1719.

748. Dendale P, Scherrenberg M, Sivakova O, Frederix I. Prevention: From the cradle to the grave and beyond. Eur J Prev Cardiol. 2019;26(5):507-11. doi:10.1177/2047487318821772.

749. Копылова О. В., Ершова А. И., Мешков А. Н., Драпкина О. М. Профилактика сердечно-сосудистых заболеваний на протяжении жизни. Часть I: Преконцепционный, пренатальный и грудной периоды. Кардиоваскулярная терапия и профилактика. 2020;19(6):117-25.

750. Vermeulen R, Schymanski EL, Barabási AL, Miller GW. The exposome and health: Where chemistry meets biology. Science (80- ). 2020;367(6476):392-6. doi:10.1126/science.aay3164.

751. Daiber A, Lelieveld J, Steven S, et al. The “exposome” concepthow environmental risk factors influence cardiovascular health. Acta Biochim Pol. 2019;66(3):269-83. doi:10.18388/abp.2019_2853.

752. E H, E A, M H. The preconceptional period as an opportunity for prediction and prevention of noncommunicable disease. Best Pract Res Clin Obstet Gynaecol. 2015;29(1):54-62. doi:10.1016/J.BPOBGYN.2014.05.011.

753. Corchia C, Mastroiacovo P. Health promotion for children, mothers and families: Here’s why we should “think about it before conception.” Ital J Pediatr. 2013;39(1):68. doi:10.1186/1824-7288-39-68.

754. Marczylo EL, Amoako AA, Konje JC, et al. Smoking induces differential miRNA expression in human spermatozoa: a potential transgenerational epigenetic concern? Epigenetics. 2012;7(5):432-9. doi:10.4161/epi.19794.

755. Yu Z, Han S, Zhu J, Sun X, Ji C, Guo X. Pre-Pregnancy Body Mass Index in Relation to Infant Birth Weight and Offspring Overweight/Obesity: A Systematic Review and MetaAnalysis. PLoS One. 2013; 8(4):e61627. doi:10.1371/journal.pone.0061627.

756. McPherson NO, Owens JA, Fullston T, Lane M. Preconception diet or exercise intervention in obese fathers normalizes sperm microRNA profile and metabolic syndrome in female offspring. Am J Physiol — Endocrinol Metab. 2015;308(9):E805-E821. doi:10.1152/ajpendo.00013.2015.

757. Antonarakis SE. Carrier screening for recessive disorders. Nat Rev Genet. 2019;20(9):549-561. doi:10.1038/s41576-019-0134-2.

758. Revazyan KZ, Meshkov AN, Ershova AI, et al. Psychosocial, ethical, legal and economic aspects of genetic screening for the carriage of variants that cause the development of monogenic recessive diseases. Profil Meditsina. 2021;24(2):102-8. doi:10.17116/profmed202124021102.

759. Revazyan KZ, Meshkov AN, Ershova AI, et al. Genetic screening for heterozygous carriage of mutations that cause the development of monogenic recessive diseases. Profil meditsina. 2020;23(6):111. doi:10.17116/profmed202023062111.

760. Arabin B, Baschat AA. Pregnancy: An Underutilized Window of Opportunity to Improve Long-term Maternal and Infant HealthAn Appeal for Continuous Family Care and Interdisciplinary Communication. Front Pediatr. 2017;5:69. doi:10.3389/fped.2017.00069.

761. U S, JB A, B S, JF T. Perinatal Origins of Adult Disease. Neonatology. 2018;113(4):393-399. doi:10.1159/000487618.

762. Rodríguez-Rodríguez P, Ramiro-Cortijo D, Reyes-Hernández CG, et al. Implication of oxidative stress in fetal programming of cardiovascular disease. Front Physiol. 2018;9:602. doi:10.3389/fphys.2018.00602.

763. Agosti M, Tandoi F, Morlacchi L, Bossi A. Nutritional and metabolic programming during the first thousand days of life. Pediatr Med Chir. 2017;39(2):157. doi:10.4081/pmc.2017.157.

764. Peters SAE, Van Der Schouw YT, Wood AM, et al. Parity, breastfeeding and risk of coronary heart disease: A pan-European case-cohort study. Eur J Prev Cardiol. 2016;23(16):1755-65. doi:10.1177/2047487316658571.

765. Clark MM, Hildreth A, Batalov S, et al. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation. Sci Transl Med. 2019;11(489). doi:10.1126/scitranslmed.aat6177.

766. Dron JS, Hegele RA. The evolution of genetic-based risk scores for lipids and cardiovascular disease. Curr Opin Lipidol. 2019;30(2):71-81. doi:10.1097/MOL.0000000000000576.

767. Ceyhan-Birsoy O, Ceyhan-Birsoy O, Murry JB, et al. Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. Am J Hum Genet. 2019;104(1):76-93. doi:10.1016/j.ajhg.2018.11.016.

768. Abrignani MG, Lucà F, Favilli S, et al. Lifestyles and Cardiovascular Prevention in Childhood and Adolescence. Pediatr Cardiol. 2019;40(6):1113-25. doi:10.1007/s00246-019-02152-w.

769. Whitebread D, Bingham S. Habit Formation and Learning in Young Children. https://mascdn.azureedge.net/cms/themoney-advice-service-habit-formation-and-learning-in-youngchildren-may2013.pdf.

770. Childhood Obesity Surveillance Initiative. https://www.euro.who.int/__data/assets/pdf_file/0019/400654/COSI-Severe-ObesityFS-ENG-LowRes.pdf. Accessed April 5, 2021.

771. Nittari G, Scuri S, Petrelli F, et al. Fighting obesity in children from European World Health Organization member states. Epidemiological data, medical-social aspects, and prevention programs. Clin Ter. 2019;170(3):e223-e230. doi:10.7417/CT.2019.2137.

772. Villegas-Navas V, Montero-Simo MJ, Araque-Padilla RA. The Effects of Foods Embedded in Entertainment Media on Children’s Food Choices and Food Intake: A Systematic Review and Meta-Analyses. Nutrients. 2020;12(4):964. doi:10.3390/nu12040964.

773. Баланова Ю. А., Имаева А. Э., Концевая А. В. и др. Маркетинг продуктов питания и напитков на телевизионных каналах с детской аудиторией в Российской Федерации. Профилактическая медицина. 2018;21(5):98-106. doi:10.17116/profmed20182105198.

774. Singhal A. The role of infant nutrition in the global epidemic of non-communicable disease. Proc Nutr Soc. 2016;75(2):162-8. doi:10.1017/S0029665116000057.

775. Hoey H. Management of obesity in children differs from that of adults. In: Proceedings of the Nutrition Society. Cambridge University Press. 2014;73:519-525. doi:10.1017/S0029665114000652.

776. Raghuveer G, White DA, Hayman LL, et al. Cardiovascular Consequences of Childhood Secondhand Tobacco Smoke Exposure: Prevailing Evidence, Burden, and Racial and Socioeconomic Disparities: A Scientific Statement from the American Heart Association. Circulation. 2016;134(16):e336-e359. doi:10.1161/CIR.0000000000000443.

777. Münzel T, Hahad O, Kuntic M, et al. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J. 2020;41(41):4057-70. doi:10.1093/eurheartj/ehaa460.

778. Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(9):1030-45. doi:10.1016/j.jacc.2018.06.036.

779. Александров А. А., Розанов В. Б., Котова М. Б. и др. Раннее начало курения и изменения показателей ожирения, уровня артериального давления и липидного спектра крови у лиц мужского пола: результаты 26-летнего проспективного исследования. Кардиоваскулярная терапия и профилактика. 2020;19(5):2610. doi:10.15829/1728-8800-2020-2610.

780. Александров А. А., Бубнова М. Г., Кисляк О. А. Рекомендации по профилактике сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российский кардиологический журнал. 2012;(6s1):1-39.

781. Morgan PJ, Collins CE, Plotnikoff RC, et al. The “Healthy Dads, Healthy Kids” community randomized controlled trial: A community-based healthy lifestyle program for fathers and their children. Prev Med (Baltim). 2014;61:90-9. doi:10.1016/j.ypmed.2013.12.019.

782. Mikkelsen BE. Policies to promote on physical activity and healthy eating in kindergartens from theory to practice. Int J Pediatr Obes. 2011;6(SUPPL. 2):8-11. doi:10.3109/17477166.2011.613653.

783. Centers for Disease Control and Prevention (CDC). School health guidelines to promote healthy eating and physical activity. MMWR Recomm Rep. 2011;60(RR-5):1-76.

784. Haas J, Baber M, Byrom N, et al. Changes in student physical health behaviour: an opportunity to turn the concept of a Healthy University into a reality. Perspect Public Health. 2018;138(6):316-24. doi:10.1177/1757913918792580.

785. Baker R, Taylor E, Essafi S, et al. Engaging young people in the prevention of noncommunicable diseases. Bull World Health Organ. 2016;94(7):484. doi:10.2471/BLT.16.179382.

786. Kopylova OV, Rakovskaya YS, Yakunchikova MS, Savchuk PO. Medical Volunteers and their role in CVD prevention. Eur Heart J. 2021;42(11):1057-9. doi:10.1093/eurheartj/ehaa1013.

787. Roberge JB, Van Hulst A, Barnett TA, et al. Lifestyle Habits, Dietary Factors, and the Metabolically Unhealthy Obese Phenotype in Youth. J Pediatr. 2019;204:46-52.e1. doi:10.1016/j.jpeds.2018.08.063.

788. Medic G, Wille M, Hemels MEH. Short- and long-term health consequences of sleep disruption. Nat Sci Sleep. 2017;9:151-61. doi:10.2147/NSS.S134864.

789. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210. doi:10.3322/CAAC.21557.

790. NCD Countdown 2030: worldwide trends in noncommunicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet (London, England). 2018;392(10152):1072-88. doi:10.1016/S0140-6736(18)31992-5.

791. Schmidt H. Chronic Disease Prevention and Health Promotion. 2016. In: H. Barrett D, W. Ortmann L, Dawson A, Saenz C, Reis A, Bolan G, editors. Public Health Ethics: Cases Spanning the Globe [Internet]. Cham (CH): Springer; 2016. Chapter 5. https://doi.org/10.1007/978-3-319-23847-0_5

792. WHO/Europe | Nutrition — Infographic — 9 global targets for noncommunicable diseases for 2025. https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/data-and- statistics/infographic-9-global-targets-for-noncommunicablediseases-for-2025. Accessed October 24, 2021.

793. Концевая А. В., Анциферова А. А., Калинина А. М. и др. Обзор отечественного опыта реализации корпоративных программ укрепления здоровья, направленных на коррекцию поведенческих факторов риска. Профилактическая медицина. 2021; 24(1):109-17. doi: 10.17116/profmed202124011109.

794. Schopp LH, Bike DH, Clark MJ, Minor MA. Act Healthy: Promoting health behaviors and self-efficacy in the workplace. Health Educ Res. 2014;30(4):542-53. doi:10.1093/her/cyv024.

795. Dent E, Hoogendijk EO. Psychosocial Resources: Moderators or Mediators of Frailty Outcomes? J Am Med Dir Assoc. 2015;16(3):258-9. doi:10.1016/j.jamda.2014.11.014.

796. Muller M, Smulders YM, De Leeuw PW, Stehouwer CDA. A critical role for frailty? Hypertension. 2014;63(3):433-41. doi:10.1161/HYPERTENSIONAHA.113.00911.

797. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. PLoS One. 2014;9(7):e102149. doi:10.1371/journal.pone.0102149.

798. Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. J Am Med Assoc. 2015;314(1):52-60. doi:10.1001/jama.2015.7008.

799. Lahrouchi N, Raju H, Lodder EM, et al. Utility of PostMortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. J Am Coll Cardiol. 2017;69(17):2134-45. doi:10.1016/j.jacc.2017.02.046.

800. Lacour P, Buschmann C, Storm C, et al. Cardiac Implantable Electronic Device Interrogation at Forensic Autopsy: An Underestimated Resource? Circulation. 2018;137(25):2730-40. doi:10.1161/CIRCULATIONAHA.117.032367.

801. Engel GL. The need for a new medical model: A challenge for biomedicine. Science (80- ). 1977;196(4286):129-36. doi:10.1126/science.847460.

802. Wade DT, Halligan PW. The biopsychosocial model of illness: A model whose time ha come. Clin Rehabil. 2017;31(8):995-1004. doi:10.1177/0269215517709890.

803. Children & Non-Communicable Disease: Global Burden Report 2019. https://www.ncdchild.org/wp-content/uploads/2021/03/ncdchild_global_burden-report-2019.pdf.

804. WHO&FAO. Human energy requirements. Report of a Joint FAO/WHO/UNU Expert Consultation Rome, 17-24 October 2001. World Health Organization, Food and Agriculture Organization of the United Nations, United Nations University Publ., 2004.

805. Pediatric Nutrition in Practice. (Editor Koletzko B). 2nd ed. Karger; 2015. doi:10.1159/isbn.978-3-318-02691-7.

806. WHO Guidelines: Saturated fatty acid and trans-fatty intake for adults and children. Published 2018. https://extranet.who.int/dataform/upload/surveys/666752/files/Draft%20WHO%20SFATFA%20guidelines_04052018%20Public%20Consultation(1).pdf

807. Hyseni L, Bromley H, Kypridemos C, et al. Systematic review of dietary trans-fat reduction interventions. Bull World Health Organ. 2017;95(12):821-830G. doi:10.2471/BLT.16.189795.

808. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ. 2013; 346:e7492. doi:10.1136/bmj.e7492.

809. Global Strategy for Infant and Young Child Feeding. WHO-UNICEF. 2003. http://apps.who.int/iris/bitstream/handle/10665/42590/9241562218.pdf?sequence=1

810. Conducting an initiative to create favorable conditions for breastfeeding in hospitals. Juana Willumsen Consultant to WHO, Department of Nutrition for Health and Development. 2013. (In Russ.) Проведение инициативы по созданию в больницах благоприятных условий для грудного вскармливания. Juana Willumsen консультант ВОЗ, Департамент по питанию для здоровья и развития. 2013 г. http://www.who.int/elena/bbc/implementation_bfhi/ru.

811. СанПиН 2.3/2.4.3590-20 “Санитарно-эпидемиологические требования к организации общественного питания населения”, утв. Постановл. Главного государственного санитарного врача РФ от 27.10.2020г №32.

812. WHO. Child growth standards. Published 2006. https://www.who.int/tools/child-growth-standards.

813. Оценка физического развития детей и подростков: методические рекомендации. Российская ассоциация эндокринологов; авторы-составители: Петеркова В. А. и др. М., 2017. 96 с.

814. Diagnosis and treatment of obesity in children and adolescents. In: Federal clinical guidelines (Protocols) for the treatment of children with endocrine diseases. Edited by I. I. Dedov and V. A. Peterkova. M.: Praktika, 2014. pp. 163-83. (In Russ.) Диагностика и лечение ожирения у детей и подростков. В кн.: Федеральные клинические рекомендации (протоколы) по лечению детей с эндокринными заболеваниями. Под ред. И.И. Дедова и В.А. Петерковой. М.: Практика, 2014. c. 163-83.

815. WHO guidelines on physical activity and sedentary behaviour: at a glance. WHO 2020. https://www.who.int/publications/i/item/9789240014886.

816. Guidelines on physical activity, sedentary behaviour and sleep for children under 5 years of age. Geneva: World Health Organization, 2019. https://apps.who.int/iris/handle/10665/311664.

817. Оказание медицинской помощи детскому населению в центрах здоровья для детей. Методические рекомендации. Москва, 2017.

818. Приказ Министерства здравоохранения РФ от 10 августа 2017 г. N 514н “О Порядке проведения профилактических медицинских осмотров несовершеннолетних” (с изменениями и дополнениями).

819. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future. National Survey Results on Drug Use, 1975-2009. Volume I, Secondary School Students. NIH Publication Number 10-7584, Natl. Inst. Drug Abus., vol. I, pp. 1–773, 2010.

820. Patrick ME, Terry-McElrath Y, Miech RA, et al. Current HighIntensity Drinking Among Eighth and Tenth Grade Students in the U. S. Am. J. Prev. Med. 2017;53(6):904-908.

821. Здравоохранение в России 2019. Статистический сборник. Росстат.2019.

822. Skvortsova ES, Lushkina NP. The main changes in alcohol consumption by rural teenage schoolchildren in Russia over 15 years. 2019. ss. 102-8. (In Russ.) Скворцова Е. С., Лушкина Н. П. Основные изменения потребления алкоголя сельскими подростками-школьниками в России за 15 лет. 2019. сс. 102-8.

823. Kuchma VR, Sokolova SB. Basic trends in behavioral health risks. Heal. Risk Anal. 2019;8(2):4-13.

824. Скворцова Е. С., Постникова Л. К. Характеристика потребления психоактивных веществ подростками, учащимися учреждений начального профессионального образования Великого Новгорода. Вестник Новгородского государственного университета. Серия: Медицинские науки. 2018;(2):77-82. https://portal.novsu.ru/vestnik/vestnik/i.78099/?article=1456468.

825. Brown SA, McGue M, Maggs J, et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics. 2008;121 Suppl 4(Suppl 4):S290-310. doi:10.1542/peds.2007-2243D.

826. Григорьева А. А., Амелина Е. М. Роль профилактики употребления психоактивных веществ для предотвращения суицидального поведения в подростковом возрасте. Вопросы наркологии. 2021;(3):71-83. doi:10.47877/0234-0623_2021_03_71.

827. Grant BF, Dawson DA. Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 1998;10(2):163-73. doi:10.1016/s0899-3289(99)80131-x.

828. Squeglia LM, Jacobus J, Tapert SF. The influence of substance use on adolescent brain development. Clin EEG Neurosci. 2009;40(1):31-8. doi:10.1177/155005940904000110.

829. Ford CA, Millstein SG, Halpern-Felsher BL, Irwin CE Jr. Influence of physician confidentiality assurances on adolescents’ willingness to disclose information and seek future health care. A randomized controlled trial. JAMA. 1997;278(12):1029-34.

830. Millstein SG, Marcell AV. Screening and counseling for adolescent alcohol use among primary care physicians in the United States. Pediatrics. 2003;111(1):114-22. doi:10.1542/peds.111.1.114.

831. Приказ Министерства здравоохранения РФ от 6 октября 2014 г N 581н “О Порядке проведения профилактических медицинских осмотров обучающихся в общеобразовательных организациях и профессиональных образовательных организациях, а также образовательных организациях высшего образования в целях раннего выявления незаконного потребления наркотических средств и психотропных веществ” (с изменениями и дополнениями)”. https://base.garant.ru/70832674/

832. Yarnall AJ, Sayer AA, Clegg A, Rockwood K, Parker S, Hindle JV. New horizons in multimorbidity in older adults. Age Ageing. 2017;46(6):882-888. doi: 10.1093/ageing/afx150.

833. Kirchberger I, Meisinger C, Heier M, et al. Patterns of multimorbidity in the aged population. Results from the KORA-Age study. PLoS One. 2012;7(1):e30556. doi:10.1371/journal.pone.0030556.

834. Шальнова C. А., Яровая Е. Б., Макарова Ю. К. и др. Одинаков ли риск смертности от сердечно-сосудистых заболеваний и от всех причин у российских мужчин со стенокардией и/или с перемежающейся хромотой? Данные популяционного проспективного исследования. Рациональная Фармакотерапия в Кардиологии. 2020;16(5):787-97.

835. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. doi:10.1161/CIR.0b013e31820a55f5.

836. Bauersachs R, Zannad F. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection? Thromb Haemost. 2018;118(S 01):S12-S22. doi:10.1055/s-0038-1636530.

837. Шальнова С. А., Яровая Е. Б., Куценко В. А. и др. Оценка риска общей и сердечно-сосудистой смертности у российских мужчин с различными вариантами болевого синдрома в нижних конечностях. Кардиоваскулярная терапия и профилактика. 2020;19(4):2560. doi:10.15829/1728-8800-2020-2560.

838. Шальнова С. А., Евстифеева С. Е., Деев А. Д. и др. Вклад маркеров воспаления и ишемической болезни сердца в общую и сердечно-сосудистую смертность у пожилых жителей мегаполиса (данные исследования sahr). Российский кардиологический журнал. 2015;(6):7-13. doi:10.15829/1560-4071-2015-6-7-13.

839. Yap AF, Thirumoorthy T, Kwan YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatr Gerontol Int. 2016;16(10):1093-101. doi:10.1111/ggi.12616.

840. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-67. doi:10.1093/eurheartj/ehab312.

841. Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Распространенность курения в России. Что изменилось за 20 лет? Профилактическая медицина. 2015;18(6):47-52. doi:10.17116/profmed201518647-52.

842. Choi W, Kim SH, Kang SH, et al. Differential impact of smoking on cardiac or non-cardiac death according to age. PLoS One. 2019;14(10):e0224486. doi:10.1371/journal.pone.0224486.

843. West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):1018-36. doi:10.1080/08870446.2017.1325890.

844. Our World in Data. Alcohol Consumption. https://ourworldindata.org/alcohol-consumption (accessed: 14.02.2021).

845. Knott CS, Coombs N, Stamatakis E, Biddulph JP. All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ. 2015;350:h384. doi:10.1136/bmj.h384.

846. Forster LE, Pollow R, Stoller EP. Alcohol use and potential risk for alcohol-related adverse drug reactions among communitybased elderly. J Community Health. 1993;18(4):225-39. doi:10.1007/BF01324433.

847. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. doi:10.1161/CIRCULATIONAHA.115.018912.

848. Wright JD, Hughes JP, Ostchega Y, et al. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001-2008. Natl Health Stat Report. 2011;(35):1-22, 24.

849. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197-205. doi:10.1016/j.jash.2015.01.002.

850. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. doi:10.1016/j.diabres.2017.03.024.

851. Yakaryılmaz FD, Öztürk ZA. Treatment of type 2 diabetes mellitus in the elderly. World J Diabetes. 2017;8(6):278-85. doi:10.4239/wjd.v8.i6.278.

852. Newson RS, Felix JF, Heeringa J, et al. Association between serum cholesterol and noncardiovascular mortality in older age. J Am Geriatr Soc. 2011;59(10):1779-85. doi:10.1111/j.1532-5415.2011.03593.x.

853. Yi SW, Yi JJ, Ohrr H. Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. Sci Rep. 2019;9(1):1596. doi:10.1038/s41598-018-38461-y.

854. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997;96(1):37-43.

855. Tchkonia T, Morbeck DE, Von Zglinicki T, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010;9(5):667-84. doi:10.1111/j.1474-9726.2010.00608.x.

856. Jura M, Kozak LP. Obesity and related consequences to ageing. Age (Dordr). 2016;38(1):23. doi:10.1007/s11357-016-9884-3.

857. Wang Z. Age-dependent decline of association between obesity and mortality: a systematic review and meta-analysis. Obes Res Clin Pract. 2015;9(1):1-11. doi:10.1016/j.orcp.2014.01.006.

858. Millán-Calenti JC, Tubío J, Pita-Fernández S, et al. Prevalence of cognitive impairment: effects of level of education, age, sex and associated factors. Dement Geriatr Cogn Disord. 2009;28(5):455-60. doi:10.1159/000257086.

859. Duan J, Lv YB, Gao X, et al. Association of cognitive impairment and elderly mortality: differences between two cohorts ascertained 6-years apart in China. BMC Geriatr. 2020;20(1):29. doi:10.1186/s12877-020-1424-4.

860. Boyle PA, Buchman AS, Wilson RS, et al. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch Neurol. 2009;66(11):1339-44. doi:10.1001/archneurol.2009.240.

861. Auyeung TW, Lee JS, Kwok T, Woo J. Physical frailty predicts future cognitive decline — a four-year prospective study in 2737 cognitively normal older adults. J Nutr Health Aging. 2011;15(8):690-4. doi:10.1007/s12603-011-0110-9.

862. Musich S, Wang SS, Hawkins K, Greame C. The Frequency and Health Benefits of Physical Activity for Older Adults. Popul Health Manag. 2017;20(3):199-207. doi:10.1089/pop.2016.0071.

863. Hoogendijk EO, Afilalo J, Ensrud KE, et al. Frailty: implications for clinical practice and public health. Lancet. 2019; 394 (10206):1365-75. doi: 10.1016/S0140-6736(19)31786-6.

864. Nascimento CM, Ingles M, Salvador-Pascual A, et al. Sarcopenia, frailty and their prevention by exercise. Free Radic Biol Med. 2019;132:42-9. doi:10.1016/j.freeradbiomed.2018.08.035.

865. Forsman AK, Schierenbeck I, Wahlbeck K. Psychosocial interventions for the prevention of depression in older adults: systematic review and meta-analysis. J Aging Health. 2011;23(3):387-416. doi:10.1177/0898264310378041.

866. Regitz-Zagrosek V, Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. Physiol Rev. 2017;97(1):1-37. doi:10.1152/physrev.00021.2015.

867. Oliver-Williams CT, Heydon EE, Smith GC, et al. Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. Heart. 2013;99:1636-44.

868. Wagner MM, Bhattacharya S, Visser J, et al. Association between miscarriage and cardiovascular disease in a Scottish cohort. Heart. 2015;101:1954-60.

869. Heida KY, Velthuis BK, Oudijk MA, et al. Dutch Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with a history of spontaneous preterm delivery: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23:253-63.

870. Nilsson PM, Li X, Sundquist J, Sundquist K. Maternal cardiovascular disease risk in relation to the number of offspring born small for gestational age: national, multi-generational study of 2.7 million births. Acta Paediatr. 2009;98:985-9.

871. Sondergaard MM, Hlatky MA, Stefanick ML, et al. Association of adverse pregnancy outcomes with risk of atherosclerotic cardiovascular disease in postmenopausal women. JAMA Cardiol. 2020;5:1390-8.

872. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10:e003497.

873. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209. doi:10.1016/j.jacc.2018.11.002. Erratum in: J Am Coll Cardiol. 2019;73(24):3234-7.

874. Honigberg MC, Zekavat SM, Aragam K, et al. Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol. 2019;74:2743-54.

875. Basit S, Wohlfahrt J, Boyd HA. Pre-eclampsia and risk of dementia later in life: nationwide cohort study. BMJ. 2018;363:k4109.

876. Committee on Practice Bulletins — Obstetrics. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131:e49-e64.

877. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8:639-49.

878. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62:905-14.

879. American Diabetes Association. 16. Diabetes Advocacy: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2020;43(Suppl 1):S203-S204. doi:10.2337/dc20-S016.

880. Matthews KA, Kuller LH, Sutton-Tyrrell K, et al. Changes in cardiovascular RF during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke. 2011;32:1104-11.

881. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi:10.1001/jama.288.3.321.

882. Moyer VA. Menopausal hormone therapy for the primary prevention of chronic conditions: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(1):47-54. doi:10.7326/0003-4819-158-1-201301010-00553.

883. Marjoribanks J, Farquhar C, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:Cd004143. doi:10.1002/14651858.CD004143.pub5.

884. Lee SC, Phillips M, Bellinge J, et al. Is breast arterial calcification associated with coronary artery disease?-A systematic review and meta-analysis. PLoS One. 2020;15(7):e0236598. doi:10.1371/journal.pone.0236598.

885. Ruzicic D, Dobric M, Vukovic M, et al. The correlation of SYNTAX score by coronary angiography with breast arterial calcification by digital mammography. Clinical Radiology. 2018;73:454-9. doi:10.1016/j.crad.2017.12.002.

886. Yildiz S, Toprak H, Aydin S, Bilgin M, Oktay V, Abaci O, Kocas C. The association of breast arterial calcification and metabolic syndrome. Clinics (Sao Paulo). 2014;69(12):841-846. https://doi.org/10.6061/clinics/2014(12)09

887. Reddy J, Bilezikian JP, Smith SJ, Mosca L. Reduced bone mineral density is associated with breast arterial calcification. J Clin Endocrinol Metab. 2008;93(1):208-11. doi:10.1210/jc.2007-0693.

888. Iribarren C, Sanchez G, Lu M, et al. Association of Breast Arterial Calcification Presence and Gradation with the Ankle-Brachial Index among Postmenopausal Women. Eur J Cardiovasc Med. 2018;5(5):544-51.

889. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1265-73. doi:10.1001/jamacardio.2020.3557pmid:32730619.

890. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 PostAcute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-5. doi:10.1001/jama.2020.12603.

891. Johansson M, Ståhlberg M, Runold M, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep 2021;3:573-80. doi:10.1016/j.jaccas.2021.01.009.

892. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020;11:4302-4. doi:10.19102/icrm.2020.111102.

893. Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30:449-51. doi:10.1007/s10286-020-00727-9

894. Umapathi T, Poh MQW, Fan BE, et al. Acute hyperhidrosis and postural tachycardia in a COVID-19 patient. Clin Auton Res. 2020;30:571-3. doi:10.1007/s10286-020-00733-x

895. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021;21:e63-7. doi:10.7861/clinmed.2020-0896

896. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, et al. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin Immunol. 2020;214:108384. doi:10.1016/j.clim.2020.108384

897. Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2021;18:508 9. doi:10.1016/j.hrthm.2020.12.007.

898. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline. 2020. https://www.nice.org.uk/guidance/ng188.

899. National Institute for Health and Care Excellence. Stable angina: management clinical guideline. 2016. https://www.nice.org.uk/Guidance/CG126.

900. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management NICE guideline. 2021. https://www.nice.org.uk/guidance/ng196.

901. National Institute for Health and Care Excellence. Acute coronary syndromes NICE guideline. 2020. https://www.nice.org.uk/guidance/ng185.

902. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.

903. Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol. 2017;17(2):83‐96.

904. Libby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018;72(17):2071‐81.

905. Trinder M, Walley KR, Boyd JH, et al. Causal inference for genetically determined levels of high‐density lipoprotein cholesterol and risk of infectious disease. Arterioscler Thromb Vasc Biol. 2020;40(1):267‐78.

906. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169‐96.

907. Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 2007;178(1):496‐502.

908. Bacchetti T, Campanati A, Ferretti G, et al. Oxidative stress and psoriasis: the effect of antitumour necrosis factor‐α inhibitor treatment. Br J Dermatol. 2013;168(5):984‐9.

909. Farid AS, Horii Y. Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis. Lipids Health Dis. 2012;11:92.

910. Профилактика осложнений, диспансерное наблюдение и ведение на амбулаторном этапе лиц, перенесших новую коронавирусную инфекцию (COVID-19). Временные методические рекомендации Версия 1 (14.08.2020).

911. Драпкина О. М., Дроздова Л. Ю., Бойцов С. А. и др. Временные методические рекомендации: “Оказание амбулаторно-поликлинической медицинской помощи пациентам с хроническими заболеваниями, подлежащими диспансерному наблюдению, в условиях пандемии COVID-19” Профилактическая медицина. 2020;23(3) (Приложение).

912. Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020;30:100631. doi:10.1016/j.ijcha.2020.100631.

913. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy [published correction appears in Eur Heart J. 2020;41(48):4591]. Eur Heart J. 2020;41(19):1821-9. doi:10.1093/eurheartj/ehaa388.

914. Gopinathannair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020;59(2):329-36. doi:10.1007/s10840-020-00789-9.

915. Romiti GF, Corica B, Lip GYH, Proietti M. Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021;10(11):2490. doi:10.3390/jcm10112490.

916. Taha ME, Alsafi W, Taha M, et al. Coronavirus Disease and NewOnset Atrial Fibrillation: Two Cases. Cureus. 2020;12(5):e8066. doi:10.7759/cureus.8066.

917. Seecheran R, Narayansingh R, Giddings S, et al. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection. J Investig Med High Impact Case Rep. 2020;8:2324709620925571. doi:10.1177/2324709620925571.

918. Robinson B, Wang L, Fu X, et al. COVID-19 severity in asthma patients: A multi-center matched cohort study. doi:10.1101/2020.10.02.20205724. Preprint. medRxiv.

919. Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110. doi:10.1038/s41598-017-09536.

920. Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. Diabetes Metab. 2020;46(4):265-71. doi:10.1016/j.diabet.2020.05.008.

921. Crouse AB, Grimes T, Li P, et al. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front Endocrinol (Lausanne). 2021;11:600439. doi:10.3389/fendo.2020.600439.

922. Ambrosetti M, Abreu A, Corra U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2020:2047487320913379.

923. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8.

924. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Netwok. Arch Intern Med. 2008;168:2194-204.

925. Verschueren S, Eskes AM, Maaskant JM, et al. The effect of exercise therapy on depressive and anxious symptoms inpatients with ischemic heart disease: A systematic review. J Psychosom Res. 2018;105:80-91.

926. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016:CD001800.

927. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019;1:CD003331.

928. Salzwedel A, Jensen K, Rauch B, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol. 2020;27:1756-774.

929. Santiago de Araujo Pio C, Marzolini S, Pakosh M, et al. Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Meta-regression Analysis. Mayo Clin Proc. 2017;92:1644-59.

930. van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol. 2017;232:294-303.

931. Santiago de Araujo Pio C, Chaves GS, Davies P, et al. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev. 2019;2:CD007131.

932. Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nursecoordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart. 2013;99:1421-30.

933. Jennings C, Kotseva K, De Bacquer D, et al. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. Eur Heart J. 2014;35:1411-20.

934. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;371:1999-2012.

935. Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2017;6:CD007130.

936. Jin K, Khonsari S, Gallagher R, et al. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2019;18:260-71.

937. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659-72.

938. Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies — The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol. 2016;23:1914-39.

939. Hammill BG, Curtis LH, Schulman KA, et al. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation. 2010;121:63-70.

940. Doimo S, Fabris E, Piepoli M, et al. Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: a long-term followup study. Eur Heart J. 2019;40:678-85. doi:10.1093/eurheartj/ehy417.

941. Бубнова М. Г., Аронов Д. М. Клинические эффекты годичной программы кардиореабилитации с применением физических тренировок после острого инфаркта миокарда у больных трудоспособного возраста с разным реабилитационным потенциалом. Кардиоваскулярная терапия и профилактика. 2019;18(5):27-37. doi:10.15829/1728-8800-2019-5-27-37.

942. Taylor RS, Walker S, Smart NA, et al. ExTraMATCH II Collaboration. Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant MetaAnalysis. J Am Coll Cardiol. 2019;73:1430-43.

943. Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletespatients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40:13-8.

944. Hansen D, Rovelo Ruiz G, Doherty P, et al. EAPC EXPERT working group. Do clinicians prescribe exercise similarly in patients with different cardiovascular diseases? Findings from the EAPC EXPERT working group survey. Eur J Prev Cardiol. 2018;25:682-91.

945. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac Rehabilitation: A Systematic Review and Meta-regression. Sports Med Open. 2017;3:19.

946. Iyengar RN, Le Francois AL, Henderson RR, et al. Medication Nonadherence Among edicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel. J Manag Care Spec Pharm. 2016;22(5):550-60. doi:10.18553/jmcp.2016.22.5.550.

947. Rawstorn JC, Gant N, Direito A, et al. Telehealth exercisebased cardiac rehabilitation: a systematic review and meta-analysis. Heart. 2016;102(15):1183-92. doi:10.1136/heartjnl-2015-308966.

948. Shields GE, Wells A, Doherty P, et al. Cost-effectiveness of cardiac rehabilitation: a systematic review. Heart. 2018; 104:1403-10.

949. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105-14. doi:10.1016/0895-4356(88)90084-4.

950. Ощепкова Е. В. Пятилетние итоги реализации федеральной целевой программы “Профилактика и лечение артериальной гипертонии в Российской Федерации” (2002-2006 годы). Атмосфера. Новости кардиологии. 2007;1:23-6.

951. Научно-организационный комитет проекта ЭССЕ-РФ Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина. 2013;6:25-34.

952. Баланова Ю. А., Имаева А. Э, Концевая А. В. и др. Эпидемиологический мониторинг факторов риска хронических неинфекционных заболеваний в практическом здравоохранении на региональном уровне. Методические рекомендации. Под редакцией Бойцова С. А. 2016. 111 c. doi:10.17116/profmed2016metod01.

953. Баланова Ю. А., Капустина А. В., Шальнова С. А. и др. Поведенческие факторы риска в российской популяции: результаты обследования по модифицированной методологии STEPS. Профилактическая медицина. 2020;23(5):56-66. doi:10.17116/profmed20202305156.

954. Шальнова С. А., Баланова Ю. А., Деев А. Д. и др. Интегральная оценка приверженности здоровому образу жизни как способ мониторинга эффективности профилактических мер. Профилактическая медицина. 2018;21(4):65-72. doi:10.17116/profmed201821465.

955. Шальнова С. А., Максимов С. А., Баланова Ю. А. и др. Приверженность к здоровому образу жизни в российской популяции в зависимости от социально-демографических характеристик населения. Кардиоваскулярная терапия и профилактика. 2020;19(2):2452. doi:10.15829/1728-8800-2020-2452.

956. Федеральная служба государственной статистики РФ. Выборочное наблюдение состояния здоровья населения. Итоги 2020г. https://gks.ru/free_doc/new_site/ZDOR20/PublishSite_2020/index.html (accessed: 25.09.2021).

957. Федеральный закон о государственном регулировании производства и оборота этилового спирта, алкогольной и спиртосодержащей продукции и об ограничении потребления (распития) алкогольной продукции. 22 ноября 1995 года N 171-ФЗ. http://www.consultant.ru/document/cons_doc_LAW_8368/. (23.10.2021).

958. Федеральный закон “О внесении изменений в статью 16 Федерального закона “О государственном регулировании производства и обо рота этилового спирта, алкогольной и спиртосодержащей продукции и об ограничении потребления (распития) алкогольной продукции” от 24.04.2020 N 145-ФЗ. http://www.consultant.ru/document/cons_doc_LAW_351160/.

959. Decree of the Government of the Russian Federation No. 612 of September 27, 2007. (In Russ.) Постановление Правительства РФ от 27 сентября 2007 года № 612. http://pravo.gov.ru/proxy/ips/?docbody=&nd=102116923. (15.06.2021).

960. WHO Committee of Experts on Problems Related to Alcohol Consumption. The second report. (In Russ.) Комитет экспертов ВОЗ по проблемам, связанных с потреблением алкоголя. Второй доклад. https://apps.who.int/iris/bitstream/handle/10665/43670/9789244209448_rus.pdf?sequence=4.

961. Мырзаматова А. О., Концевая А. В., Горный Б. Э. и др. Меры популяционной профилактики, направленные на снижение потребления алкоголя: международный опыт и перспективы усиления мер в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2020;19(3):2566. doi:10.15829/1728-8800-2020-2566.

962. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation. 2012;126:1514-63.

963. Tackling NCDs: “Best buys” and other recommended interventions for the prevention and control of noncommunicable diseases. Geneva: WHO. 2017 (https://apps.who.int/iris/bitstream/handle/10665/259232/WHO-NMH-NVI-17.9-eng.pdf?sequence=1).

964. World Health Organization. Tobacco. WHO. https://www.who.int/ru/news-room/fact-sheets/detail/tobacco

965. Hill C. Prévention et dépistage des cancers. Bulletin du Cancer. 2013;100:6.

966. Chisholm D, Moro D, Bertram M, et al. Are the “best buys” for alcohol control still valid? An update on the comparative cost-effectiveness of alcohol control strategies at the global level. J Stud Alcohol Drugs. 2018;79:514-22. doi:10.15288/jsad.2018.79.514.

967. Wagenaar A, Tobler A, Komro K. Effects of alcohol tax and price policies on morbidity and mortality: a systematic review. Am J Public Health. 2010;100;11:2270-8. doi:10.2105/AJPH.2009.186007.

968. Scarborough P, Adhikari V, Harrington RA. Impact of the announcement and implementation of the UK Soft Drinks Industry Levy on sugar content, price, product size and number of available soft drinks in the UK, 2015-19: A controlled interrupted time series analysis. PLoS Med. 2020;17(2):e1003025. doi:10.1371/journal.pmed.1003025.

969. Colchero MA, Molina M, Guerrero-López CM. After Mexico Implemented a Tax, Purchases of Sugar-Sweetened Beverages Decreased and Water Increased: Difference by Place of Residence, Household Composition, and Income Level. J Nutr. 2017;147:1552-7.

970. Powell LM, Auld MC, Chaloupka FJ, et al. Access to fast food and food prices: relationship with fruit and vegetable consumption and overweight among adolescents. Adv Health Econ Health Serv Res. 2007;17:23-48.

971. Fiscal Policies for Diet and Prevention of Noncommunicable Diseases. Geneva: World Health Organization. 2015. https://www.who.int/docs/default-source/obesity/fiscal-policies-fordiet-and-the-prevention-of-noncommunicable-diseases-0.pdf?sfvrsn=84ee20c_2

972. Assessment of the impact of a health product tax. Copenhagen: WHO Regional Office for Europe; 2015. Accessed September 6, 2020. https://www.euro.who.int/__data/assets/pdf_file/0008/332882/assessmentimpact-PH-tax-report.pdf?ua=1

973. Moran A, Thorndike A, Franckle R, et al. Financial Incentives Increase Purchases Of Fruit And Vegetables Among LowerIncome Households With Children. Health Aff (Millwood). 2019;38(9):1557-66. doi:10.1377/hlthaff.2018.05420.

974. Waterlander WE, Steenhuis IH, de Boer MR, et al. The effects of a 25% discount on fruits and vegetables: results of a randomized trial in a three-dimensional web-based supermarket. Int J Behav Nutr Phys Act. 2012;9:11. doi:10.1186/1479-5868-9-11.

975. Lee Y, Mozaffarian D, Sy S, et al. Cost-effectiveness of financial incentivesfor improving diet and health through Medicare and Medicaid: A microsimulation study. PLoS Med. 2019;16(3):e1002761. doi:10.1371/journal.pmed.1002761.

976. Workplace Health Incentives, May 20, 2013. CDC, National Healthy worksite; https://www.cdc.gov/workplacehealthpromotion/toolsresources/pdfs/nhwp-workplace-health-incentives.pdf

977. Первая Глобальная министерская конференция по здоровому образу жизни и борьбе с неинфекционными заболеваниями (Москва, Российская Федерация, 28-29 апреля 2011).

978. Arena R, Guazzi M, Lianov L, et al. Healthy lifestyle interventions to combat noncommunicable disease — a novel nonhierarchical connectivity model for key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine. Eur Heart J 2015;36(31):2097-109. doi:10.1093/eurheartj/ehv207.

979. Анциферова А. А., Концевая А. В., Муканеева Д. К., Драпкина О. М. Neighborhood environment: влияние доступности точек по продаже алкоголя и табака на здоровье людей, проживающих на определенной территории. Кардиоваскулярная терапия и профилактика. 2021;20(6):2959. doi:10.15829/1728-8800-2021-2959.

980. Муканеева Д. К., Концевая А. В., Анциферова А. А. и др. Влияние факторов среды обитания человека на формирование пищевых привычек. Профилактическая медицина. 2021;24(11):126-31. doi:10.17116/profmed202124111ХХ.

981. Lucan SC, Maroko AR, Jin A, et al. Change in an urban food environment within a single year: Considerations for foodenvironment research and community health. Prev Med Rep. 2020;19:101102. doi:10.1016/j.pmedr.2020.101102.

982. Finan LJ, Lipperman-Kreda S, Grube JW, et al. Alcohol Marketing and Adolescent and Young Adult Alcohol Use Behaviors: A Systematic Review of Cross-Sectional Studies. J Stud Alcohol Drugs Suppl. 2020;Sup 19(Suppl 19):42-56. doi:10.15288/jsads.2020.s19.42.

983. Furr-Holden CDM, Nesoff ED, Nelson V, et al. Understanding the relationship between alcohol outlet density and life expectancy in Baltimore City: The role of community violence and community disadvantage. J Community Psychol. 2019;47(1):63-75. doi:10.1002/jcop.22099.

984. Lipton R, Ponicki WR, Gruenewald PJ, et al. Space-Time Analyses of Alcohol Outlets and Related Motor Vehicle Crashes: Associations at City and Census Block-Group Levels. Alcohol Clin Exp Res. 2018;42(6):1113-21. doi:10.1111/acer.13758.

985. Jennings JM, Milam AJ, Greiner A, et al. Neighborhood alcohol outlets and the association with violent crime in one midAtlantic City: the implications for zoning policy. J Urban Health. 2014;91(1):62-71. doi:10.1007/s11524-013-9821-z.

986. Finan LJ, Lipperman-Kreda S, Abadi M, et al. Tobacco outlet density and adolescents’ cigarette smoking: a metaanalysis. Tob Control. 2019;28(1):27-33. doi:10.1136/tobaccocontrol-2017-054065.

987. Marsh L, Vaneckova P, Robertson L, et al. Association between density and proximity of tobacco retail outlets with smoking: A systematic review of youth studies. Health Place. 2021;67:102275. doi:10.1016/j.healthplace.2019.102275.

988. Loomis BR, Kim AE, Goetz JL, et al. Density of tobacco retailers and its association with sociodemographic characteristics of communities across New York. Public Health. 2013;127(4):333-8. doi:10.1016/j.puhe.2013.01.013.

989. Astuti PAS, Mulyawan KH, Sebayang SK, et al. Cigarette retailer density around schools and neighbourhoods in Bali, Indonesia: A GIS mapping. Tob Induc Dis. 2019;17:55. doi:10.18332/tid/110004.

990. Zhao X. Health communication campaigns: A brief introduction and call for Dialogue. International Journal of Nursing Sciences. 2020;7:S11eS15.

991. Snyder LB, Hamilton MA, Mitchell EW, et al. A meta-analysis of the effect of mediated health communication campaigns on behavior change in the United States. J Health Commun. 2004;9(sup1):71e96.

992. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261e71.

993. Crosby K. How the food and drug administration convinced teens to rethink their relationship with cigarettes. Am J Prev Med. 2019;56(2):S1e4.

994. Breza E, Stanford FC, Alsan M, et al. Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial. Nature Medicine. 2021;27:1622-8.

995. de Vere Hunt I, Dunn T, Mahoney M, et al. A social mediabased campaign to promote COVID-19 vaccine uptake in underrepresented groups in the US. European Journal of Public Health. 2021;31, Supplement_3:ckab165.170. doi:10.1093/eurpub/ckab165.170.

996. Концевая А. В., Калинина А. М., Иванова Е. С. и др. Руководство для Центров общественного здоровья и медицинской профилактики. М.: ФГБУ “НМИЦ ТПМ” Минздрава России. 2021. 296 с.

997. Brownson RC, Hopkins DP, Wakefield MA. Effects of smoking restrictions in the workplace. Annu Rev Public Health. 2002;23:333-48. doi:10.1146/annurev.publhealth.23.100901.140551.

998. Mattke S, Kapinos K, Caloyeras JP, et al. Workplace Wellness Programs: Services Offered, Participation, and Incentives. Rand Health Q. 2015;5(2):7.

999. Smedslund G, Fisher KJ, Boles SM, Lichtenstein E. The effectiveness of workplace smoking cessation programmes: a meta-analysis of recent studies. Tob Control. 2004;13(2):197-204. doi:10.1136/tc.2002.002915.

1000. Hey K, Perera R. Competitions and incentives for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD004307. doi:10.1002/14651858.CD004307.pub2. Update in: Cochrane Database Syst Rev. 2008;(3):CD004307.

1001. Cook JW, Collins LM, Fiore MC, et al. Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment. Addiction. 2016;111(1):117-28. doi:10.1111/add.13161.

1002. Алкоголь. Информационный бюллетень ВОЗ. Электронный портал Всемирной организации здравоохранения. https://www.who.int/ru/news-room/factsheets/detail/alcohol.

1003. Heather N, Raistrick D, Godfrey C. A Summary of the Review of the Effectiveness of Treatment for Alcohol Problems. National Treatment Agency for Substance Misuse. 2006. https://core.ac.uk/download/pdf/34711278.pdf.

1004. Андреева Л. А., Александров А. А., Терехович Т. И. Организация медицинской профилактики чрезмерного употребления алкоголя среди работников промышленных предприятий: обзор литературы. Вопросы организации и информатизации здравоохранения. 2006;(3):44-51.

1005. Brendryen H, Johansen A, Duckert F, Nesvåg S. A Pilot Randomized Controlled Trial of an Internet-Based Alcohol Intervention in a Workplace Setting. Int J Behav Med. 2017;24(5):768-77. doi:10.1007/s12529-017-9665-0.

1006. Fernandes AC, Oliveira RC, Proença RP, et al. Influence of menu labeling on food choices in real-life settings: a systematic review. Nutr Rev. 2016;74(8):534-48. doi:10.1093/nutrit/nuw013.

1007. Brambila-Macias J, Shankar B, Capacci S, et al. Policy interventions to promote healthy eating: a review of what works, what does not, and what is promising. Food Nutr Bull. 2011;32(4):365-75. doi:10.1177/156482651103200408.

1008. Geaney F, Harrington J, Fitzgerald A, Perry I. The impact of a workplace catering initiative on dietary intakes of salt and other nutrients: a pilot study. Public Health Nutr. 2011;14(8):1345-9. doi:10.1017/S1368980010003484.

1009. Geaney F, Kelly C, Di Marrazzo JS, Harrington JM, Fitzgerald AP, Greiner BA, Perry IJ. The effect of complex workplace dietary interventions on employees’ dietary intakes, nutrition knowledge and health status: a cluster controlled trial. Prev Med. 2016;89:76-83. doi:10.1016/j.ypmed.2016.05.005.

1010. Профилактика неинфекционных болезней на рабочих местах с помощью рациона питания и физической активности: Доклад ВОЗ. Всемирного экономического форума о совместном мероприятии, 2008. https://www.who.int/dietphysicalactivity/ WHOWEF_report_JAN2008_ru.pdf?ua=1.

1011. McEachan RR, Lawton RJ, Jackson C, et al. Testing a workplace physical activity intervention: a cluster randomized controlled trial. Int J Behav Nutr Phys Act. 2011;8:29. doi:10.1186/1479-5868-8-29.

1012. Hills S, Walker M, Barry AE. Sport as a Vehicle for Health Promotion: a Shared Value Example of Corporate Social Responsibility. Sport Management Review. 2019;22(1):126-41. doi:10.1016/j.smr.2018.10.001.

1013. Labor protection is the basis of the future of the labor sphere. Based on a century of experience. ILO, 2019. (In Russ.) Охрана труда — основа будущего сферы труда. Опираясь на столетний опыт. МОТ, 2019.

1014. Гимельштейн Е. А. Управление стрессом в корпорациях с точки зрения организации рабочего пространства. 2019.

1015. European Risk Observatory Report (2009) OSH in Figures: Stress at Work Facts and Figures. https://osha.europa.eu/en/tools-and-publications/publications1015. European Agency for Safety and Health at Work, 2015. https://w w w.europarl.europa.eu/cmsdat a/104756/EU-OSHA_annual%20report_without%20letter.pdf

1016. Carneiro D, Novais P, Augusto JC, Payne N. New Methods for Stress Assessment and Monitoring at the Workplace, in IEEE Transactions on Affective Computing, 2019;10(2):237-54. doi:10.1109/TAFFC.2017.2699633.

1017. Cismaru M, Wuth A. Identifying and analyzing social marketing initiatives using a theory-based approach. Journal of Social Marketing. 2019;9(4):357-97. doi:10.1108/JSOCM-06-2018-0063.

1018. Reavley NJ, Morgan AJ, Fischer JA, et al. Effectiveness of eLearning and blended modes of delivery of Mental Health First Aid training in the workplace: randomised controlled trial. BMC Psychiatry. 2018;18(1):312. doi:10.1186/s12888-018-1888-3.

1019. Kitchener BA, Jorm AF. Mental health first aid training in a workplace setting: a randomized controlled trial [ISRCTN13249129]. BMC Psychiatr y. 2004;4:23. doi:10.1186/1471-244X-4-23.

1020. Rybakov IA. Strengthening the health of workers: evaluation of the effectiveness of corporate model programs. Motivation and remuneration. 2020;(2):116-21. (In Russ.) Рыбаков И. А. Укрепление здоровья работающих: оценка эффективности корпоративных модельных программ. Мотивация и оплата труда. 2020;(2):116-21. https://grebennikon.ru/article-3lbv.html.

1021. Рыбаков И. А. Экономическая эффективность программ по укреплению корпоративного здоровья, а также профилактических программ на рабочем месте для сотрудников с краткосрочной временной нетрудоспособностью. Биозащита и биобезопасность. 2015;(1):10-7.

1022. Smith ML, Wilson MG, DeJoy DM, et al. Chronic disease selfmanagement program in the workplace: opportunities for health improvement. Front Public Health. 2015;2:179. doi:10.3389/fpubh.2014.00179.

1023. Smith ML, Wilson MG, Robertson MM, et al. Impact of a Translated Disease Self-Management Program on Employee Health and Productivity: Six-Month Findings from a Randomized Controlled Trial. Int J Environ Res Public Health. 2018;15(5):851. doi:10.3390/ijerph15050851.

1024. Greenberg KL, Donchin M, Leiter E, Zwas DR. Health ambassadors in the workplace: a health promotion intervention mobilizing middle managers and RE-AIM evaluation of outcomes. BMC Public Health. 2021;21(1):1585. doi:10.1186/s12889-021-11609-8.

1025. Amaya M, Melnyk BM. Workplace Wellness Champions: Lessons Learned and Implications for Future Programming. Building Healthy Academic Communities Journal. 2017;1(2):59-67. doi:10.18061/bhac.v1i1.5744.

1026. Joseph B, Walker A, Fuller-Tyszkiewicz M. Evaluating the effectiveness of employee assistance programmes: a systematic review. European Journal of Work and Organizational Psychology. 2018, 27:1, 1-15. doi:10.1080/1359432X.2017.1374245.

1027. Lee D, Batra C, Knutson M. Evaluation of a Renewal Room for Nurses. Doctor of Nursing Practice Projects: College of Nursing.2021;2. https://digitalcommons.unmc.edu/con_dnp/2

1028. Niven A, Ryde GC, Wilkinson G, et al. The Effectiveness of an Annual Nationally Delivered Workplace Step Count Challenge on Changing Step Counts: Findings from Four Years of Delivery. Int J Environ Res Public Health. 2021;18(10):5140. doi:10.3390/ijerph18105140.

1029. Meyer D, Jayawar MW, Muir S, et al. Increasing Awareness of the Importance of Physical Activity and Healthy Nutrition: Results From a Mixed-Methods Evaluation of a Workplace Program. J Phys Act Health. 2019;16(4):259-66. doi:10.1123/jpah.2017-0608.

1030. Meyer D, Jayawardana MW, Muir SD, et al. Promoting Psychological Well-Being at Work by Reducing Stress and Improving Sleep: Mixed-Methods Analysis. J Med Internet Res. 2018;20(10):e267. doi:10.2196/jmir.9058.

1031. Onyishi CN, Ede MO. Rational Emotive Occupational Health Coaching in the Management of Police Subjective Well-Being and Work Ability: a Case of Repeated Measures. J Police Crim Psych. 2021;36:96-111. doi:10.1007/s11896-019-09357-y.

1032. Edman JS, Galantino ML, Hutchinson J, Greeson JM. Health coaching for healthcare employees with chronic disease: A pilot study. Work. 2019;63(1):49-56. doi:10.3233/WOR-192907.

1033. Nutbeam D. Health promotion glossary. Health Promot Int 1998;13(4):349-64.

1034. Sørensen K, Van den Broucke S, Fullam J, et al. Health literacy and public health: a systematic review and integration of definitions and models. BMC Public Health. 2012;12:80.

1035. Лопатина М. В., Попович М. В., Концевая А. В., Драпкина О. М. Детерминанты грамотности в вопросах здоровья: результаты первого популяционного исследования в Российской Федерации. Профилактическая медицина. 2021;24(12):57-65.

1036. Nutbeam D, Lloyd JE. Understanding and Responding to Health Literacy as a Social Determinant of Health. Annu Rev Public Health. 2021;42:159-73. doi:10.1146/annurevpublhealth-090419-102529.

1037. Лопатина М.В., Попович М.В., Старовойтов М.Л. и др. Измерение грамотности в вопросах здоровья на популяционном уровне. Первые результаты в Российской Федерации. Профилактическая медицина. 2020;23(5):2005-64.

1038. Health literacy for NCD prevention, management and prompting equality: How to use health literacy to understanding and responses to NCDs. Geneva: World Health Organization; 2017. https://www.who.int/global-coordination-mechanism/workinggroups/hl_youth.pdf.

1039. Tsoh JY, Sentell T, Gildengorin G, et al. Healthcare communication barriers and self-rated health in older Chinese American immigrants. Journal of Community Health. 2016;41(4):741-52.

1040. Williams MV, Baker DW, Honig EG, et al. Inadequate literacy is a barrier to asthma knowledge and self-care. Chest. 1998;114(4):1008-15.

1041. Aaby A, Friis K, Christensen B, et al. Health literacy is associated with health behaviour and self-reported health: A large population-based study in individuals with cardiovascular disease. Eur J Prev Cardiol. 2017;24(17):1880-8. doi:10.1177/2047487317729538.

1042. Kickbusch, Ilona, Pelikan, Jürgen M., Apfel, Franklin & Tsouros, Agis D. (2013). Health literacy: the solid facts. World Health Organization. Regional Office for Europe. https://apps.who.int/iris/handle/10665/326432.

1043. Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. Journal of Behavioral Medicine. 2006;29:377-87.

1044. Berkman ND, Sheridan SL, Donahue KE, et al. Low Health Literacy and Health Outcomes: An Updated Systematic Review. Ann Intern Med. 2011;155(2):97-107. doi:10.7326/0003-4819-155-2-201107190-00005.

1045. Vandenbosch J, Van den Broucke S, Vancorenland S, et al. Health literacy and the use of healthcare services in Belgium. Journal of Epidemiology and Community Health. 2016;70(10):1032-8.

1046. Pelikan JM, Ganahl K. Measuring Health Literacy in General Populations: Primary Findings from the HLS-EU Consortium’s Health Literacy Assessment Effort. Stud Health Technol Inform. 2017;240:34-59.

1047. Graham WJ, Kuruvilla S, Hinton R, et al. Multisectoral collaboration for health and sustainable development. BMJ. 2018;363:k4868.

1048. Parker RM, Hernandez LM. What makes an organization health literate? Journal of Health Communication. 2012;17(5):624-7.

1049. Trezona A, Dodson S, Osborne RH. Development of the Organizational Health Literacy Responsiveness (Org-HLR) Framework in collaboration with health and social services professionals. BMC Health Service Research. 2017;17(1):513.

1050. Harris J, Springett J, Croot L, et al. Can community-based peer support promote health literacy and reduce inequalities? A realist review. Public health research. 2015;3(3):1-192.

1051. Kickbusch I. Health literacy: An essential skill for the twenty-first century. Health Education. 2008;108(2):101-4. doi:10.1108/09654280810855559.

1052. Managing the COVID-19 infodemic: Promoting healthy behaviours and mitigating the harm from misinformation and disinformation. Geneva: World Health Organization; 2020. https://www.who.int/news/item/23-09-2020-managing-the-covid-19-

1053. infodemic-promoting-healthy-behaviours-and-mitigating-theharm-from-misinformation-and-disinformation.

1054. Swire-Thompson B, Lazer D. Public health and online misinformation: Challenges and recommendations. Annu Rev Public Health. 2020;41(1):433-51. doi:10.1146/annurevpublhealth-040119-094127.

1055. Thorndike AN, Riis J, Sonnenberg LM, Levy DE. Traffic-light labels and choice architecture: promoting healthy food choices. Am J Prev Med 2014;46:143–149.

1056. Thorndike AN, Sonnenberg L, Riis J, et al. 2-phase labeling and choice architecture intervention to improve healthy food and beverage choices. Am J Public Health. 2012;102:527-33.

1057. Vyth EL, Steenhuis IH, Vlot JA, et al. Actual use of a front-of-pack nutrition logo in the supermarket: consumers’ motives in food choice. Public Health Nutr. 2010;13:1882-9.

1058. Bleich SN, Barry CL, Gary-Webb TL, Herring BJ. Reducing sugar-sweetened beverage consumption by providing caloric information: how Black adolescents alter their purchases and whether the effects persist. Am J Public Health. 2014;104:2417-24.

1059. Концевая А. В. Программа профилактики хронических неинфекционных заболеваний в ОАО “Сбербанк России”: синтез доказательной медицины и маркетинговых технологий. Российский кардиологический журнал. 2014;(9):16-21.

1060. Краткий обзор. Положение дел в области продовольственной безопасности и питания в мире — 2020. Преобразование продовольственных систем для обеспечения финансовой доступности здорового питания. ФАО, МФСР, ЮНИСЕФ, ВПП и ВОЗ. 2020 год. Рим, ФАО. doi:10.4060/ca9699ru.

1061. The mechanism for implementing the FAO urban food agenda. Rome, Italy, 2019. 44 p. (In Russ.) Механизм осуществления городской продовольственной повестки ФАО. Rome, Italy, 2019. 44 p. ISBN: 978-92-5-132193-5. https://www.fao.org/publications/card/en/c/CA3151RU.

1062. US Food and Drug Administration. Food labeling: calorie labeling of articles of food in vending machines. Fed Regist. 2014;79:71259-93.

1063. Provision of food information to consumers, 1169/2011, European Union, 2014. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02011R1169-20180101

1064. US Food and Drug Administration. Food labeling: nutrition labeling of standard menu items in restaurants and similar retail food establishments; final rule. Fed Regist. 2014;79:71155-9.

1065. Национальное фитнес-сообщество. Официальный сайт. https://nationalfitness.ru.

1066. Фитнес-образование в школе тренеров FPA в Москве. https://fitness-pro.ru.

1067. Об университете. Российский государственный университет физической культуры, спорта, молодёжи и туризма. https://rgufk.ru.

1068. Обеспечение психологической безопасности в детско подростковой среде. Методические рекомендации для психологов общеобразовательных организаций. Под ред. Л. П. Фальковской (авт. Артамонова Е. Г., Калинина Н. В., Ефимова О. И., Салахова В. Б.). М.: ФГБНУ “Центр защиты прав и интересов детей”, 2018. 36 с.

1069. Постановление Главного государственного сани тарного врача РФ от 28 сентября 2020 г. N 28 “Об утверждении санитарных правил СП 2.4.3648-20 “Санитарно-эпидемиологические требования к организациям воспитания и обучения, отдыха и оздоровления детей и молодежи”. https://base.garant.ru/75093644.

1070. Федеральный закон от 29 декабря 2012 г. N 273-ФЗ “Об образовании в Российской Федерации”. https://base.garant.ru/70291362.

1071. Москвина А. С. Причины и профилактика школьной неуспеваемости учащихся начальной школы. Педагогика искусства. 2015;1:286-90.

1072. CINDI working group on children and youth “Healthy children in healthy families”. Euro WHO. DK-2100 COPENHAGEN, 2000.

1073. Addressing the socioeconomic determinants of healthy eating habits and physical activity levels among adolescents. WHO/HBSC FORUM, 2006.

1074. Antwi F, Fazylova N, Garcon MC, et al. The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review. JBI Libr Syst Rev. 2012;10(42 Suppl):1-14. doi:10.11124/jbisrir-2012-248.

1075. Varagiannis P, Magriplis E, Risvas G, et al. Effects of Three Different Family-Based Interventions in Overweight and Obese Children: The “4 Your Family” Randomized Controlled Trial. Nutrients. 2021;13(2):341. doi:10.3390/nu13020341.

1076. West F, Sanders MR, Cleghorn GJ, Davies PS. Randomised clinical trial of a family-based lifestyle intervention for childhood obesity involving parents as the exclusive agents of change. Behav Res Ther. 2010;48(12):1170-9. doi:10.1016/j.brat.2010.08.008.

1077. Nix RL, Francis LA, Feinberg ME, et al. Improving Toddlers’ Healthy Eating Habits and Self-regulation: A Randomized Controlled Trial. Pediatrics. 2021;147(1):e20193326. doi:10.1542/peds.2019-3326.

1078. Thorén A, Janson A, Englund E, Silfverdal SA. Development, implementation and early results of a 12-week web-based intervention targeting 51 children age 5-13 years and their families. Obes Sci Pract. 2020;6(5):516-23. doi:10.1002/osp4.440.

1079. Walter H, Sadeque-Iqbal F, Ulysse R, et al. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol. JBI Database System Rev Implement Rep. 2015;13(10):69-81. doi:10.11124/jbisrir-2015-2335.

1080. Cremers HP, Mercken L, Oenema A, de Vries H. A web-based computer-tailored smoking prevention programme for primary school children: intervention design and study protocol. BMC Public Health. 2012;12:277. doi:10.1186/1471-2458-12-277.

1081. Thomas RE, Baker PRA, Lorenzetti D. Family-based programmes for preventing smoking by children and adolescents (Review). The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 4. https://www.eprints.qut.edu.au/55759/1/CD004493_family_based_smoking.pdf

1082. Gilligan C, Wolfenden L, Foxcroft DR, et al. Family-based prevention programmes for alcohol use in young people. Cochrane Database Syst Rev. 2019;3(3):CD012287. doi:10.1002/14651858.CD012287.pub2.

1083. Lima-Serrano M, Martínez-Montilla JM, Lima-Rodríguez JS, et al. Design, implementation and evaluation of a webbased computer-tailored intervention to prevent binge drinking in adolescents: study protocol. BMC Public Health. 2018;18(1):449. doi:10.1186/s12889-018-5346-4.

1084. Лукьянова Л. М. Укрепление здоровья ребенка через формирование здорового образа жизни в семье. Наука-2020. 2019;(9):89-93.

1085. Формирование культуры здоровья на уровне семьи. ФБУЗ “Центр гигиенического образования населения” Роспотребнадзора. http://cgon.rospotrebnadzor.ru/content/62/963.

1086. Здоровая семья — здоровое поколение: материалы докладов Всероссийской научно-практической конференции с международным участием. Отв. ред. Скрябина Н. Ю.; ФГБОУ ВО РостГМУ Минздрава России, ФПК и ППС, каф. педагогики. Ростов-на-Дону: Изд-во РостГМУ, 2020. 302 с.

1087. Дубовченко Ю. Д., Тарбеев Н. Н. Здоровье семьи как физическое, психологическое и социальное благополучие ее членов. Материалы докладов Всероссийской научно-практической конференции с международным участием: Изд-во РостГМУ, 2020. сс. 61-6.

1088. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379:1529-39.

1089. Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. JACC. 2019;73:2915-29.

1090. Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18:70.

1091. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA. 2019;321:277-87.

1092. Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a metaanalysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40:607-17.

1093. Yusuf S, Joseph P, Dans A, et al. International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384:216-28.

1094. Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42:4013-24. doi:10.1093/eurheartj/ehab390.

1095. King A, Shipley M, Markus H; for the ACES Investigators. The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke. 2013;44:542-6.

1096. Park J-M, Kang K, Cho Y-J, et al. Comparative effectiveness of prestroke aspirin on stroke severity and outcome. Ann Neurol. 2016;79:560-8.

1097. Antithrombotics Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. VMJ. 2002;324:71-86.

1098. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909-19.

1099. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin inpatients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39.

1100. Ralph L. Sacco, Hans-Christoph Diener, Salim Yusuf, et al. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N Engl J Med. 2008;359:1238-51.

1101. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2018;39:213-60.

1102. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77.

1103. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.

1104. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.

1105. Bianco M, Careggio A, Destefanis P, et al. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J — Cardiovas Pharmacother. 2021;7:196-205.

1106. Benenati S, Crimi G, Canale C, et al. Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network metaanalysis. Eur Heart J — Cardiovas Pharmacother. 2022;8:56-64.

1107. Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070-8.

1108. Sibbing D, Aradi D, Jacobshagen C, et al. Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747-57.

1109. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621-31.

1110. Kim CJ, Park M-W, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, openlabel, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16.

1111. ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-73.

1112. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-51.

1113. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379:215-25.

1114. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-9.

1115. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020;383:207-17.

1116. Gargiulo G, Cannon CP, Gibson CM, et al. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulantbased randomized clinical trials. Eur Heart J — Cardiovasc Pharmacother. 2021;7:f50-f60.

1117. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23:1612-76.

1118. Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. A North American Perspective: 2021 Update. Circulation. 2021;143:583-96.

1119. Aboyans V, Ricco J-B, Bartelink M-L, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-816.

1120. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838-47.

1121. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of LowDose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497-505.

Российское национальное руководство «Приверженность лечению»

Сетевое научное издание

ГБУЗ НИИ СП им. Н.В. Склифосовского / НИИ педиатрии ЦКБ РАН / ФБУН Центральный НИИ эпидемиологии Роспотребнадзора / ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России / ФГАОУ ВО НИУ БелГУ / ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России / ФГАОУ ВО РУДН / ФГБНУ Научный центр неврологии / ФГБНУ НИИ КПССЗ / ФГБНУ Томский НИМЦ РАН / ФГБНУ ФНКЦ РР / ФГБНУ НЦПЗРЧ / ФГБНУ РНЦХ им. Б.В. Петровского / ФГБОУ ВО ВГМУ Минздрава России / ФГБОУ ВО КГМУ Минздрава России / ФГБОУ ВО МГМСУ им. А.И. Евдокимова Минздрава России / ФГБОУ ВО МГУ им. М.В. Ломоносова / ФГБОУ ВО МГУПП / ФГБОУ ВО ОмГМУ Минздрава России / ФГБОУ ВО НИМГУ им. Н.П. Огарева / ФГБОУ ВО ОрГМУ
Минздрава России / ФГБОУ ВО ПСПбГМУ им. акад. И.П. Павлова Минздрава России / ФГБОУ ВО «РАНХиГС при Президенте Российской Федерации» / ФГБОУ ВО РостГМУ Минздрава России / ФГБОУ ВО РязГМУ Минздрава России / ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава России / ФГБОУ ВО СГМУ Минздрава России / ФГБОУ ВО СЗГМУ
им. И.И. Мечникова / ФГБОУ ВО СибГМУ Минздрава России / ФГБОУ ВО СтГМУ Минздрава России / ФГБОУ ВО Тверской ГМУ Минздрава России / ФГБОУ ВО УГУ / ФГБОУ ВО ЮУГМУ Минздрава России / ФГБОУ ДПО РМАНПО Минздрава России / ФГБУ «ФНИЦЭМ им. Н.Ф. Гамалеи» Минздрава России / ФГБУ НМХЦ им. Н.И. Пирогова Минздрава России / ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России / ФГБУ «НМИЦ кардиологии им. Е.И. Чазова» Минздрава России / ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России / ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России / ФГБУ НМИЦ ПН им. В.М. Бехтерва Минздрава России / ФГБУ НМИЦ АГП им. В.И. Кулакова, ФГБУ «НМИЦ ТПМ» Минздрава России / ФГБУ «НМИЦ ФПИ» Минздрава России / ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России / ФГБУ «ГВКГ им. Н.Н. Бурденко» Минобороны России / ФГБУ «ЦЭККМП» Минздрава России

Редакционный совет

д.м.н. Николаев Н.А., акад. РАН Мартынов А.И., к.м.н. Скирденко Ю.П., акад. РАН Авдеев С.Н., чл.-корр. РАН Анисимов В.Н., чл.-корр. РАН Арутюнов Г.П., акад. РАН Ашрафян Л.А., проф. Бабунашвили А.М., чл.-корр. РАН Балыкова Л.А., акад. РАН Барбараш О.Л., проф. Васильева И.А., д.м.н. Виноградов О.И., акад. РАН Гинцбург А.Л., акад. РАН Горелов А.В., акад. РАН Драпкина О.М., акад. РАН Иоселиани Д.Г., акад. РАН Карпов Р.С., чл.-корр. РАН Кобалава Ж.Д., акад. РАН Конради А.О., проф. Лазебник Л.Б., чл.-корр. РАН. Ливзан М.А., акад. РАН
Мазуров В.И., чл.-корр. РАН Мартов А.Г., чл.-корр. РАН Марьяндышев А.О., чл.-корр. РАН Моисеев С.В., акад. РАН Намазова-Баранова Л.С., проф. Незнанов Н.Г., проф. Омельяновский В.В., акад. РАН Петров В.И., акад. РАН Поддубная И.В., акад. РАН Полушин Ю.С., акад. РАН Попов С.В., акад. РАН Ройтберг Г.Е., проф. Ройтман Е.В., чл.-корр. РАН Румянцев С.А., чл.-корр. РАН Рычкова Л.В., чл.-корр. РАН Скворцова В.И., чл.-корр. РАН Софронов А.Г., чл.-корр. РАН Танашян М.М., акад. РАН Тахчиди Х.П., чл.-корр. РАН Ткачёва О.Н., чл.-корр. РАН Фадеев В.В., Федяева В.К., акад. РАН Хубутия М.Ш.

Рабочая группа и Комитет экспертов

акад. РАН Авдеев С.Н., Агафонова Ю.А., проф. Агеев Ф.Т., Андреев К.А., чл.-корр. РАН Анисимов В.Н., чл.-корр. РАН Арутюнов Г.П., проф. Ахмедов В.А, акад. РАН Ашрафян Л.А., к.м.н. Бабичева Л.Г., проф. Бабунашвили А.М., чл.-корр. РАН Балыкова Л.А, акад. РАН Барбараш О.Л., проф. Васильева И.А., проф. Викторова И.А., д.м.н. Виноградов О.И., проф. Волчегорский И.А., проф. Галявич А.С., к.м.н. Гаус О.В., акад. РАН Гинцбург А.Л., к.м.н. Гомберг В.Г., Горбенко А.В., акад. РАН Горелов А.В., к.м.н. Горшков А.Ю., акад. РАН Драпкина О.М., д.м.н. Ершов А.В., д.м.н. Ефремова Е.В., проф. Задионченко В.С., проф. Зайцев А.А., Захарова Т.Д., проф. Зырянов С.К., акад. РАН Иоселиани Д.Г., проф. Каневская С.С., акад. РАН Карпов Р.С., д.м.н. Кашталап В.В., чл.-корр. РАН Кобалава Ж.Д., проф. Колбасников С.В., к.п.н. Кондратьева К.О., акад. РАН Конради А.О., проф. Кореннова О.Ю., д.м.н. Корпачева О.В., проф. Лазебник Л.Б., проф. Лебедев О.И., чл.-корр. РАН. Ливзан М.А., д.м.н. Лутова Н.Б., акад. РАН Мазуров В.И., проф. Малявин А.Г., проф. Мареев В.Ю., чл.-корр. РАН Мартов А.Г., акад. РАН Мартынов А.И., чл.-корр. РАН Марьяндышев А.О., акад. РАН Медведева И.В., к.м.н. Михайлова Н.Б., чл.-корр. РАН. Моисеев С.В., д.м.н. Морозова О.Л., акад. РАН Намазова-Баранова Л.С., д.м.н. Напалков Д.А., проф. Недошивин А.О., проф. Незнанов Н.Г., проф. Нечаева Г.И., проф. Никифоров В.С., д.м.н. Николаев Н.А., проф. Омельяновский В.В., Орджоникидзе М.К., проф. Павлинова Е.Б., д.м.н. Пашков А.В., проф. акад. РАН Петров В.И., Писклаков А.В., акад. РАН Поддубная И.В., акад. РАН Полушин Ю.С., акад. РАН Попов С.В., проф. Ребров А.П., акад. РАН Ройтберг Г.Е., проф. Ройтман Е.В., чл.-корр. РАН Румянцев С.А., чл.-корр. РАН Рычкова Л.В., д.м.н. Савельева И.В., проф. Сайфутдинов Р.И., к.м.н. Селимзянова Л.Р., д.м.н. Семиглазова Т.Ю., чл.-корр. РАН Скворцова В.И., к.м.н. Скирденко Ю.П., проф. Совалкин В.И., к.м.н. Советкина Н.В., к.м.н. Сорокин М.Ю., чл.-корр. РАН Софронов А.Г., проф. Стремоухов А.А., д.м.н. Сурков А.Н., чл.-корр. РАН Танашян М.М., акад. РАН Тахчиди Х.П., проф. Терентьев В.П., чл.-корр. РАН Ткачёва О.Н., к.м.н. Токарская Е.А., д.м.н. Тотчиев Г.Ф., Тулупов Р.В., проф. Тумян Г.С., проф. Тюрин В.П., д.м.н. Усов Г.М., д.м.н. Устинова Н.В., чл.-корр. РАН Фадеев В.В., Федорин М.М., Федяева В.К., д.м.н. Фофанова Т.В., акад. РАН Хубутия М.Ш., к.м.н. Шепель Р.Н., проф. Ягода А.В., проф. Якушин С.С.

Укажите регион, чтобы мы точнее рассчитали условия доставки

Начните вводить название города, страны, индекс, а мы подскажем

Например: 
Москва,
Санкт-Петербург,
Новосибирск,
Екатеринбург,
Нижний Новгород,
Краснодар,
Челябинск,
Кемерово,
Тюмень,
Красноярск,
Казань,
Пермь,
Ростов-на-Дону,
Самара,
Омск